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Abstract
Hepatocellular carcinoma (HCC) is a global health problem with poor prognosis and
limited therapeutic options. While the clinical risk factors for HCC are well described, the
precise molecular and metabolic mechanisms contributing to malignant transformation re-
main largely unknown. Recently, the Hippo signaling pathway has been identified as a key
regulator of cellular proliferation, organ size, and tumorigenesis in numerous tissues, includ-
ing the liver. However, the metabolic impact of the pathway in supporting liver growth and
tumorigenesis has not been studied. The zebrafish, Danio rerio, has successfully been ap-
plied as a model to investigate signaling pathways important in organ development to model
liver development and cancer. Here, we utilize the zebrafish to investigate the functional
and metabolic roles of the Hippo pathway in liver development and cancer in vivo.
Using a transgenic zebrafish model with liver-specific activation of the transcriptional
co-activator Yap, the downstream target of the Hippo pathway, we show Yap is functionally
conserved in its ability to promote embryonic and adult hepatomegaly. These livers demon-
strate signs of dysplasia and increased tumor susceptibility upon chemical carcinogen expo-
sure. Using transcriptomic and metabolomic analysis, we discover that nitrogen metabolism
is significantly altered in Yap-transgenic livers. Yap upregulates glutamine synthetase (Glul)
expression leading to elevated steady-state levels of glutamine, which significantly contributes
to its ability to enhance liver growth and de novo purine biosynthesis.
To further probe the functional and metabolic role of Yap prior to liver outgrowth, we
utilize yap knockout zebrafish and heat-shock inducible transgenic zebrafish that modulate
Yap activity to examine early liver development. We show Yap is important for hepatoblast
formation and expansion. Further, Yap modulates glucose uptake and glycolytic flux into
iii
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de novo nucleotide synthesis. Overall, this dissertation reveals novel roles of Yap in cellular
metabolism to support proliferation and growth by directing glucose into the building blocks
of DNA in the context of development and cancer.
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Chapter 1
Introduction
Cancer is a devastating disease with more than 1.6 million people newly diagnosed each
year and more than 1,600 people dying each day in the United States alone (Society, 2015).
While there have been numerous advances in the fundamental knowledge, detection, and
treatment of cancer, the relentless morbidity and mortality of this disease indicates that we
still have much to learn about the mechanisms underlying this complex disease in order to
develop better therapies. Originating from normal, healthy cells, cancer is in its very nature
insidious as it co-opts normal cellular processes to proliferate and transform. This is aptly
described by Siddhartha Mukherjee:
That this seemingly simple mechanism—cell growth without barriers—can lie
at the heart of this grotesque and multifaceted illness is a testament to the
unfathomable power of cell growth. Cell division allows us as organisms to grow,
to adapt, to recover, to repair—to live. And distorted and unleashed, it allows
cancer cells to grow, to flourish, to adapt, to recover, and to repair—to live at
the cost of our living. Cancer cells can grow faster, adapt better. They are more
perfect versions of ourselves (Mukherjee, 2010).
Understanding the mechanisms behind our normal ability to grow, especially in the context of
development, will allow us to better understand the basis for how cancer can metamorphose
our healthy tissues into unchecked tumors with fatal potential.
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One key question in developmental growth that has remained poorly understood is how
organs are able to grow to their appropriate sizes and then halt their continued growth. The
Hippo signaling pathway has recently been identified as a key regulator of organ size by
controlling proliferation, differentiation and apoptosis. When hijacked, these fundamental
cellular processes in normal development are at the heart of cancer’s ability to proliferate
unchecked.
In 2000, Hanahan and Weinberg outlined in a landmark paper the hallmarks of cancer,
which they define to be (1) self-sufficiency in growth signals, (2) insensitivity to anti-growth
signals, (3) evading apoptosis, (4) limitless replicative potential, (5) sustained angiogene-
sis, and (6) tissue invasion and metastasis (Hanahan and Weinberg, 2000). Mutations in
oncogenic pathways are known to cause misexpression of genes involved in these traditional
features. However, more recently, cancer studies have recognized an additional hallmark, the
deregulation of metabolism to support the high energy and biosynthesis demands of rapidly
proliferating cells (Hanahan and Weinberg, 2011). Interestingly, some of these same known
cancer pathways, such as MYC, RAS and p53, can coordinate this reprogramming of cellular
metabolism and form central regulators of cancer formation (Cairns et al., 2011).
The Hippo pathway, when deregulated, can cause overgrowth in multiple tissues, and
as such it has been postulated to be important for human cancer. Studies in mammalian
systems where the Hippo pathway is perturbed have supported this hypothesis, and exami-
nation of human carcinomas has revealed Hippo pathway deregulation (Harvey et al., 2013).
Greater understanding of how the Hippo pathway can coordinate these cellular processes,
especially to meet the metabolic demands to promote proliferation and growth are needed.
Towards this end, the study of the Hippo pathway in liver development and cancer is espe-
cially useful. As described in the story of Prometheus, the liver has the unique capability
to regenerate to its original mass following up to two-thirds resection. Its special plasticity
offers unique advantages to the study of the mechanisms behind its development and growth.
More importantly, liver cancer is the second leading cause of cancer death in men worldwide,
2
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and sixth most common cause of cancer death in women (Jemal et al., 2011). Investigating
how the Hippo pathway can contribute to liver cancer and support uncontrolled cellular
proliferation, especially at the metabolic level, can further our understanding of these im-
mortal cells and will ultimately allow us to develop novel therapeutic targets to treat this
abominable disease.
1.1 Cellular Metabolism
Metabolism is central to providing the energetics and building blocks necessary for cellular
proliferation, whether in the physiological role of development or in the pathogenic case
of cancer. The initial discovery that cancer cells have unique metabolic requirements due
to their highly proliferative nature was described by Otto Warburg almost a century ago
(Warburg et al., 1926; Ferreira et al., 2012; Warburg, 1956). With the advance of genetic
understanding of cancers and the boon of oncogenes and tumor suppressors, cancer metabolic
studies were relegated to the sidelines for a period of time. However, it soon became clear
that many key oncogenic signaling pathways converge to modulate tumor cell metabolism to
support their growth and survival, thereby pushing tumor metabolism back to the forefront
of cancer research (Cairns et al., 2011). Recent advances in metabolomics and metabolic
flux analysis, high-throughput sequencing data, and computational power have advanced
the study of these metabolic pathways and their regulation.
In normal, non-proliferating cells, the metabolic program serves to maintain homeostasis;
however, self-renewing stem cells and cancer cells must balance the catabolic demands to
support proliferation with the anabolic demands of macromolecule synthesis. Glucose is a
primary source of energy and carbon for biomolecular synthesis. With one mole of glucose,
up to 38 moles of ATP can be generated in normal aerobic conditions through oxidative
phosphorylation (OxPhos). Glycolysis breaks down glucose into pyruvate, which is then
further oxidized in the mitochondria to fuel the TCA cycle. The TCA cycle produces car-
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bon intermediates as well as NADH and FADH2 that then in turn fuel OxPhos for ATP
production. In contrast, anaerobic conditions cause glucose metabolism to truncate at the
level of glycolysis with reduction of pyruvate to lactate, generating only 2 moles of ATP per
mole glucose. In cancer cells and stem cells, a different paradigm has been found in which
glucose is primarily processed by glycolysis regardless of the availability of oxygen (aerobic
glycolysis, or the Warburg effect), instead of the more energetically favorable OxPhos (War-
burg, 1956; Koppenol et al., 2011; Vander Heiden et al., 2009). Alterations to the PI3K
pathway, HIF1, MYC, AMPK, p53, and OCT1 have all been shown to promote aerobic
glycolysis in cancer cells (Cairns et al., 2011). Moreover, in numerous studies of embryonic
stem cells in vitro, it has been shown that undifferentiated cells have high rates of glycoly-
sis and lactate production independent of oxygen state (Chung et al., 2007; Kondoh et al.,
2007; Prigione et al., 2010; Varum et al., 2011; Zhang et al., 2011b). As they differentiate,
glycolytic flux decreases and the more energetically favorable mitochondrial respiration pre-
dominates. Conversely, reprogramming of differentiated cells to iPS cells shows a reversal
to aerobic glycolysis from OxPhos (Shyh-Chang et al., 2013a). Furthermore, low oxygen
conditions promoting glycolysis enhanced the ability to generate iPS cells whereas pharma-
cological inhibition of glycolysis or stimulation of OxPhos impaired iPS cell reprogramming
(Yoshida et al., 2009; Folmes et al., 2011). This increased flux of glucose through glycolysis
in undifferentiated cells is thought to promote biosynthetic pathways by providing glycolytic
intermediates necessary for amino acid, lipid, and nucleotide synthesis. Supporting this con-
jecture, mouse ES cells show increased activity in the pentose phosphate pathway (PPP),
which generates ribose 5-phosphate for the synthesis of nucleic acids (Filosa et al., 2003;
Manganelli et al., 2012).
In the developing embryo, the first cell fate decision to inner cell mass and trophectoderm
occurs as proliferation and metabolic activity increases. Glucose transporters GLUT1 and
GLUT3 (SLC2A1 and SLC2A3) are upregulated and hexokinase (HK) and phosphofructok-
inase 1 (PFK1) are activated, increasing glycolytic flux (Pantaleon and Kaye, 1998; Shyh-
4
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Chang et al., 2013a). With this increase in glycolytic flux, lactate synthesis also increases.
OxPhos rates in general are increased; however, this is largely due to the trophectoderm.
Similar to the ES cell culture, which is derived from the inner cell mass, there is lower
OxPhos due to a decreased mitochondrial membrane potential (Shyh-Chang et al., 2013a).
Cancer cells were described over a hundred years ago to have this same increase in glycol-
ysis and lactate production even in the presence of oxygen, which was termed the Warburg
effect. While previously postulated to be due to limited energetic resources and the fact that
glycolysis has the capacity to generate ATP faster than OxPhos, this hypothesis appears
not to be the predominant mechanism given that cells using aerobic glycolysis also demon-
strate high ATP/ADP and NADH/NAD+ ratios (Vander Heiden et al., 2009). Furthermore,
cells possess finely tuned sensors to energy status and will activate signaling pathways to
reactivate catabolic metabolism when their ability to make ATP from glucose is impaired
(Vander Heiden et al., 2009). Instead, cancer cells are likely utilizing aerobic glycolysis for
biomass production to meet the high biosynthetic demands of rapid cellular proliferation.
Further evidence supporting this concept came from studies of pyruvate kinase isoenzymes,
which are responsible for the final, rate-limiting, ATP-generating step of glycolysis in which
phosphoenolpyruvate is converted to pyruvate (Mazurek et al., 2005). The PKM2 isoenzyme
was found in self-renewing cells such as stem cells and is also expressed in many tumor cells.
Interestingly, PKM2 is ineffective at promoting glycolysis (Mazurek et al., 2005; Christofk
et al., 2008). Hence, this finding was ignored for many years because it seemed counterin-
tuitive that there would be a tumor-specific isoenzyme that countered the Warburg effect.
Closer examination eventually revealed that PKM2 provided an advantage to tumors because
by inhibiting the final step in glycolysis, it promoted shunting of upstream metabolites to
critical anabolic pathways such as the PPP, hexosamine biosynthetic pathway, UDP-glucose
synthesis, glycerol synthesis, and the generating of NADPH reducing equivalents (Vander
Heiden et al., 2009; Fang et al., 2010; Guertin and Sabatini, 2007).
Similar to mouse ES cells, cancer cells show increased activity in the PPP, generating
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ribose 5-phosphate for de novo nucleotide synthesis as well as NADPH, which is required for
reductive biomacromolecule synthesis and contributes to the defense of redox stress (May-
ers and Vander Heiden, 2015). Glucose metabolites also provide components for fatty acid
synthesis, glycosylation, and glycerol components of triacylglycerides and membrane phos-
pholipids.
Not only is glucose used as a fuel and biomass supporter but glutamine also plays a sig-
nificant role in supporting cellular proliferation. Glutamine is the most abundant free amino
acid in human serum and is a requirement for proliferating cells in vitro (Cantor and Saba-
tini, 2012). With most of the glucose-derived carbon being shunted to the pentose phosphate
pathway, hexosamine biosynthetic pathway, and lipid synthesis pathways, glutamine oxida-
tion allows cells to sustain the TCA cycle by replenishing intermediates that are depleted.
Moreover, in proliferating cells, glutamine is used as the nitrogen donor for biosynthesis of
nucleotides, nonessential amino acids, and hexosamines (Hensley et al., 2013). Interestingly,
oncogenic pathways can differentially regulate glucose and glutamine consumption to ensure
a supply of energy and precursors for macromolecular synthesis. Mutant KRAS causes glu-
tamine to be transaminated to alpha-ketoacids whereas increased MYC favors glutaminolysis
with nitrogen released as ammonia (Mayers et al., 2014). This ability for oncogenic pathways
to reprogram cellular metabolism brings questions as to other pathways central to growth
and proliferation that could be influencing the cellular metabolic state.
1.2 The Hippo Signaling Pathway
1.2.1 The Core Signaling Cascade
The Hippo pathway was first identified in Drosophila melanogaster by genetic screens aimed
to identify key regulators of tissue growth in which loss of function mutations in core compo-
nents resulted in massively overgrown organs due to increased cell proliferation and resistance
to pro-apoptotic signals (Justice et al., 1995; Xu et al., 1995; Tapon et al., 2002; Dong et al.,
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2007). The first component of the Hippo pathway identified by these means was the kinase
Warts (Wts; also known as Lats), which upon deletion caused cellular hyperproliferation and
epithelial overgrowths (Justice et al., 1995; Xu et al., 1995). Additional studies identified
the Sterile 20-like (STE20) kinase Hippo (Hpo) and the scaffolding proteins Salvador (Sav)
and Mob as tumor suppressor (Mats) as tumor suppressor genes that resulted in similar
overgrowth phenotypes from increased cellular proliferation and decreased apoptosis (Tapon
et al., 2002; Harvey et al., 2003; Jia et al., 2003; Pantalacci et al., 2003; Udan et al., 2003;
Wu et al., 2003; Lai et al., 2005). These four proteins were then identified through bio-
chemical studies to form the core kinase cassette of the Hippo pathway (Figure 1.2.1) (Wu
et al., 2003; Huang et al., 2005; Lai et al., 2005). Briefly, Sav and Mats mediate complex
formation and propagate a cascade of phosphorylation leading to the activation and phos-
phorylation of Wts by Hpo (Pan, 2010; Varelas and Wrana, 2012). A yeast-two hybrid screen
for Wts-interacting proteins identified the downstream effector of the Hippo kinase cascade
to be the transcriptional co-activator Yorkie (Yki) (Huang et al., 2005). Gain-of-function
mutations in Yki produce similar overgrowth phenotypes to the loss-of-function mutations
seen in the upstream Hippo kinase cascade (Huang et al., 2005). Activated Wts directly
phosphorylates Yki to inhibit its translocation to the nucleus by promoting its interaction
with 14-3-3 proteins and its retention in the cytoplasm (Dong et al., 2007; Oh and Irvine,
2008). Yki, in its unphosphorylated state, associates with the transcription factor Scalloped
(Sd) in the nucleus and activates a transcriptional profile promoting cellular proliferation
and anti-apoptosis (Oh and Irvine, 2008; Goulev et al., 2008; Zhang et al., 2008).
The Hippo pathway is highly conserved, and all of the core components of the pathway
have direct mammalian orthologs. Similar to Drosophila, the core of the signaling cascade
in mammals consists of the STE20 protein kinases MST1 and MST2 (homologs of Hpo),
which phosphorylate and activate the kinases LATS1 and LATS2 (homologs of Wts) with
the aid of adaptor proteins SAV1 (homolog to Sav) and MOBKL1A and MOBKL1B (ho-
mologs of Mats) (Dong et al., 2007; Ramos and Camargo, 2012). Active LATS1 and LATS2
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Figure 1.2.1: Hippo Signaling in Drosophila and Mammals. (A) The Hippo path-
way in Drosophila melanogaster and (B) in mammals has more than 35 known proteins in
the pathway. Multiple upstream pathways feed into the Hippo pathway. Here, the core
signaling cascade is depicted. (A) The core kinase Hippo (Hpo) phosphorylates the kinase
Warts (Wts) as well as the scaffolding proteins Salvador (Sav) and Mobs as tumor suppressor
(Mats). Wts is then activated to phosphorylate the transcriptional co-activator Yorki (Yki),
and phosphorylation at S168 causes it to be sequested in the cytoplasm and bind the 14-3-3
protein. When Yki is unphosphorylated, it translocates to the nucleus and binds its tran-
scription factor Scalloped (Sd) and activates transcription that results in cell proliferation.
(B) In mammals, signaling through the Hippo core kinase cassette is conserved. Mammalian
MST1/2 phosphorlyates the kinase LATS1/2 to activate it, resulting in phosphorylation of
Yap at multiple sites. Specifically, phosphorylation at S127 causes Yap to interact with the
14-3-3 protein and prevent translocation to the nucleus. Further, phosphorylation at S381
primes YAP for phosphorylation by CK1ε/δ, which further targets YAP for degradation.
When the Hippo pathway is not active, YAP is able to localize to the nucleus and bind its
transcriptional partner TEAD to drive transcription of pro-proliferative and anti-apoptotic
genes.
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phosphorylate the transcriptional co-activators Yes-associated protein (YAP) and transcrip-
tional co-activator with PDZ-binding motif (TAZ), which are homologs to Yki. LATS1/2
phosphorylation of YAP and TAZ results in the cytoplasmic retention of the transcriptional
co-activators by 14-3-3 binding, and thereby inhibits their nuclear translocation and activa-
tion. Similar to Yki, YAP and TAZ lack DNA binding domains and require association with
transcription factors to execute their transcriptional activities. While a number of transcrip-
tion factors have been found to interact with YAP and TAZ, the best described are those in
the Transcriptional enhancer activator domain (TEAD) family (homologs to Sd). Further
supporting the high degree of conservation of the Hippo kinase cascade, Drosophila lacking
members of the core signaling cascade are able to be phenotypically rescued with expression
of their respective human homologs (Wu et al., 2003; Huang et al., 2005; Lai et al., 2005).
1.2.2 YAP
The Hippo signaling cascade serves to regulate the activity of Yes-associated protein (YAP), a
transcriptional co-activator. YAP was first identified as a binding partner of proto-oncogene
Yes through its interaction with the Src homology (SH3) domain (Sudol, 1994). Subsequent
cloning of the gene revealed a modular protein with various motif structures and identified
for the first time the WW domain, a conserved domain characterized by the presence of
two tryptophan residues spaced 20-22 amino acids apart (Figure 1.2.2) (Sudol, 1994; Sudol
et al., 1995). These WW domains are important for mediating interactions with other
proteins, specifically those containing PPxY motifs (Sudol and Harvey, 2010; Sudol et al.,
2012). YAP also contains a transcriptional activation domain and a PDZ-binding motif. The
transcriptional activation domain constitutes the carboxyl terminus of YAP and resembles
that found in the herpesvirus VP16 protein (Yagi et al., 1999). When the DNA-binding
domain of GAL4 is fused to the transcriptional activation domain of YAP, it demonstrates
strong transcriptional activation (Yagi et al., 1999). Further, this domain is required for
its transcriptional activation of the TEAD factors. Its acidic makeup suggests that it can
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Figure 1.2.2: Schematic of the modular domains of human YAP. YAP is a 65 KDa
protein with multiple distinct domains. YAP contains a proline-rich (P-rich) region at the
N-terminus, tandem WW domains, a Src homology 3 (SH3) domain, a coiled-coil (CC)
domain, and a PDZ-binding motif at the C-terminus. LATS1/2 phosphorylates a number
of key residues, including S127 and S384. Phosphorylation of S127 promotes cytoplasmic
retention of YAP and binding to 14-3-3. The N-terminus was mapped to be the TEAD
family binding domain (shaded in gray), and S94 is a critical residue for this interaction.
The C-terminus of YAP was found to be a strong transcriptional activator (shaded in pink).
Phosphorylation of S381 primes YAP to be phosphorylated by CK1ε/δ at S384 and S87,
targeting it for degradation.
similarly initiate transcription by interacting directly with components of the transcriptional
machinery (Vassilev et al., 2001). In addition to the transcriptional activation domain, a
PDZ-binding motif, which binds PDZ domains, is also found in the carboxyl terminus of
YAP. This PDZ-binding motif, composed of the five terminal amino acids, is critical for its
nuclear translocation (Oka and Sudol, 2009).
Importantly, YAP activity is modulated through a number of post-translational modifi-
cations, many of which have been studied and modified both in vitro and in vivo. Active
LATS1/2, which contain PPxY motifs, interact with YAP through its WW domain and
phosphorylate a number of residues on YAP, including the key serine residue S127 in hu-
man YAP (S112 in mouse YAP, S87 in zebrafish Yap) which is responsible for regulating
YAP localization. Phosphorylation of S127 in human YAP, and its respective residues in its
homologs, promotes the interaction of YAP with 14-3-3 and results in its cytoplasmic seques-
tration (Basu et al., 2003; Zhao et al., 2007). LATS1/2 also phosphorylates S61, S109, S164,
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and S381. Phosphorylation of S381 primes YAP for further phosphorylation by CK1ε/δ
kinases within a phosphodegron sequence. This additional phosphorylation then recruits the
SCFβ-TRCP ubiquitin ligase for subsequent ubiquitaination and degradation of YAP (Zhao
et al., 2010).
1.2.3 The Role of Hippo Signaling in Development and Cancer
Emerging evidence has revealed that the Hippo pathway plays a critical role as a regulator of
development, stem cell maintenance and tumorigenesis. Genetic ablation of various Hippo
pathway members results in severe developmental defects in mice and demonstrates the
importance of Hippo signaling in early embryonic development. Deletion of YAP in mice, for
example, is embryonic lethal at approximately E8.5 with defects in yolk sac vasculogenesis,
chorioallantoic fusion, and embryonic axis elongation (Morin-Kensicki et al., 2006). Deletion
of TAZ, in contrast, results in a less dramatic phenotype of renal cysts and pulmonary
emphysematous changes in mice that is not embryonic lethal (Hossain et al., 2007; Tian
et al., 2007; Makita et al., 2008). However, when both YAP and TAZ are deleted, these
double-knockout mice fail to develop past the 16-32 cell stage pre-implantation (Nishioka
et al., 2009). YAP and TAZ normally are differentially nuclear localized to the less compacted
outer cells of the blastocyst, and thereby activate TEAD to induce a trophectoderm-specific
transcriptional program. With loss of YAP and TAZ, though, the embryo is unable to
undergo this first cell fate decision, underscoring its importance in stem cell fate (Nishioka
et al., 2009).
The role of YAP and TAZ in embryonic stem (ES) cells has been further studied in vitro
and numerous studies have given evidence to support their role in cell fate specification and
maintenance of pluripotency. In studies of mouse ES cells, Yap was required to maintain
pluripotency, and its expression was reduced upon differentiation (Lian et al., 2010). Further,
expression of a nuclear mutant Yap that is constitutively active prevented ES differentiation
in vitro (Lian et al., 2010). YAP was also found to be essential for reprogramming mouse
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embryonic fibroblasts into induced pluripotent stem (iPS) cells, which resemble embryonic
stem cells in their pluripotency potential (Takahashi and Yamanaka, 2006). In human ES
cells, studies have shown Yap to be integrated with critical growth factor signals required
for maintaining the pluripotent state, specifically the transforming growth factor β (TGFβ)
family. Yap forms a complex with TEADs as well as SMAD2/3, the downstream effectors
of the TGFβ signaling pathway, and the core stem cell regulator OCT4 in human ES cells
to regulate the expression of pluripotent target genes (Beyer et al., 2013).
Not only has the Hippo pathway been shown to be important in ES cells but it also has
been implicated in the regulation of progenitor cell populations in a range of organs in line
with its role as a key regulator of organ size. YAP has been found to be nuclear localized to
progenitor cell compartments in a number of tissues, including the small intestine, developing
brain, skin, and muscle (Ramos and Camargo, 2012). In the intestine, overexpression of
YAP led to expansion of the progenitor stem cells in the crypts which was recapitulated
in conditional deletions of MST1/2 or SAV1 (Camargo et al., 2007; Cai et al., 2010; Zhou
et al., 2011). Similarly, in the skin, activation of YAP in the basal progenitors resulted in
their extensive proliferation (Schlegelmilch et al., 2011; Zhang et al., 2011a). In contrast, the
deletion of YAP in the epidermal stem cells resulted in a hypoplastic basal layer and failure of
skin expansion (Schlegelmilch et al., 2011). In the developing heart, the Hippo pathway has
been shown to be a regulator of cardiomyocyte proliferation and growth. Deletion of Hippo
pathway members SAV1 or LATS2 dramatically increased heart size similar to that seen with
nuclear activated Yap overexpression (Heallen et al., 2011; von Gise et al., 2012; Xin et al.,
2011). Conversely, conditional YAP deletion in the heart caused decreased cardiomyocyte
proliferation and lethal embryonic cardiac hypoplasia (von Gise et al., 2012; Xin et al., 2011).
The Hippo pathway has also been linked to tumorigenesis based on its ability to maintain
“stemness” as well as its regulation of a number of cellular properties, such as proliferation
and apoptosis, that are frequently deregulated in cancer. However, few mutations have been
discovered in Hippo pathway members to date. Rather, YAP has frequently been reported to
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be amplified and overexpressed (Harvey et al., 2013). Supporting this, YAP overexpression
in differentiated murine tissues, including the liver, gastrointestinal tract, skin, and heart,
cause significant hyperproliferation and overgrowth (Harvey et al., 2013). Tissue-specific
genetic deletions of Hippo pathway core members in mice have revealed a number of tumor
phenotypes, including cancers of the liver, breast, ovary, and skin (Harvey et al., 2013). In
humans, deregulation of the Hippo pathway, measured by the abnormal detection of YAP
in the nucleus, has been found in a number of different cancers, including hepatocellular
carcinoma, colonic adenocarcinoma, lung adenocarcinoma, ovarian carcinoma, and ductal
carcinoma of the breast (Zhao et al., 2007; Dong et al., 2007; Steinhardt et al., 2008; Harvey
et al., 2013). More importantly, Hippo pathway abnormalities have been found to correlate
with worse patient outcomes (Zhang et al., 2011; Xu et al., 2009; Wang et al., 2010).
While the Hippo pathway has been implicated in many of the hallmarks of cancer, namely
limitless replicative potential, self-sufficiency in growth signals, evasion of apoptosis, and
metastasis, the cellular mechanisms by which YAP sustains these abilities remain poorly
understood. Investigating how the Hippo pathway can control unlimited cellular proliferation
and drive cells to an undifferentiated state will further our understanding of the mechanisms
driving and supporting tumor growth.
1.3 The Liver
The liver is a vital organ responsible for a wide range of functions including metabolism,
glycogen storage, bile secretion, detoxification, protein synthesis, and digestion. The largest
internal organ of the human body, the liver is a highly specialized tissue composed mainly
of hepatocytes, which regulate hundreds of complex biochemical reactions necessary for life.
Hepatocytes work in concert with a number of other cells, including biliary epithelial cells
(cholangiocytes), endothelial cells, Kupffer cells, and hepatic stellate cells. The working unit
of the liver is the hepatic lobule, which is defined at the histological level and consists of a
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hexagonal plate of hepatocytes that are usually one cell thick. Each of the six corners of
the lobule are bordered by a portal triad, which contains a hepatic artery, portal vein, and
bile duct (Figure 1.3.1). Blood enters the lobule through branches of the hepatic artery and
portal vein, supplying oxygen and nutrients to the organ, and then flows through a network
of sinusoids before it leaves through the central vein located in the center of the lobule.
Bile is generated by the hepatocytes and is collected first into bile caniculi that flow from
the pericentral area to the periportal area and drain into bile ducts where it is then either
secreted into the small intestine or stored in the gall bladder.
Disturbance of liver function from developmental defects, cirrhosis, or cancer results in
significant morbidity and mortality. Primary liver and intrahepatic bile duct cancers are a
global health problem, and in the United States, over 35,000 new cases will be diagnosed
and approximately 24,000 will die of those cancers (Society, 2015). Hepatocellular carcinoma
(HCC) is the most frequent malignant primary hepatic neoplasm followed by intrahepatic bile
duct cancer, or cholangiocarcinoma (CC). While the risk factors are well known, including
viral hepatitis, cirrhosis, diabetes, and alcohol consumption, the mechanisms contributing
to HCC and CC remain unknown. These tumor types unfortunately carry a poor prognosis
as we lack effective therapies to prevent or treat liver cancer. Continued investigation into
the molecular mechanisms underlying HCC and CC pathogenesis is crucial as this will reveal
new molecular targets for effective therapies.
1.3.1 Zebrafish as a Model
In order to better understand carcinogenesis, the study of organogenesis and stem/progenitor
cells can provide important insights into the signaling pathways central to cancer. The ze-
brafish, Danio rerio, offers an ideal model for the study of this intersection between devel-
opment and cancer in the liver. Native to the river basins in East India, the zebrafish was
discovered in the Ganges river by Francis Hamilton in 1822 (Hamilton, 1822). The zebrafish
is a small, striped vertebrate tropical fish that was pioneered as a model in the 1980s by
14
Chapter 1. Introduction
CV
Figure 1.3.1: . Schematic depicting the hepatic lobule of the human liver. The
portal triad, containing the hepatic artery (red), portal vein (blue), and bile duct (green)
are located at the periphery. Bile made from the hepatocytes is collected by a network
of intrahepatic bile ducts. Blood from the gastrointestinal system is drained through the
central vein (CV).
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George Streisinger at the University of Oregon, who described the generation of homozygous
diploid zebrafish to facilitate neuronal development studies and broader mutant analysis
(Streisinger et al., 1981). Genome-wide mutagenesis screens in the 1990s in Tubingen and
Boston further uncovered the ability to use the zebrafish as a platform for invertebrate-style
forward genetics to answer questions of vertebrate development (Lieschke and Currie, 2007).
The zebrafish as a model offers a number of powerful advantages. First, they have a high
fecundity and females can lay a few hundred eggs per week; secondly, embryos grow rapidly
ex utero and are optically transparent allowing for ease in visualization during development;
and thirdly, they share conservation of vertebrate organs, including the liver. Approximately
70% of human genes have zebrafish orthologs, and forward-mutagenesis screens have iden-
tified a number of conserved genes that correlate to human disease loci (Howe et al., 2013;
Santoriello and Zon, 2012).
Zebrafish are also able to develop cancers that resemble human tumors at the histolog-
ical, gene expression, and genomic levels (White et al., 2013). When zebrafish were first
suggested to be a useful cancer model in 1982, it was known that zebrafish could form tu-
mors in response to carcinogens, such as dimethylnitramine (White et al., 2013). The idea
that zebrafish could be used as a cancer model was further expanded with other common
carcinogens such as ethylnitrosurea (ENU), 7,12-dimethylbenz[a]anthracene (DMBA), and
N-methyl-nitrosoguanadine (MNNG) causing various neoplasms, including skin papillomas,
hepatocellular carcinomas, rhabdomyosarcoma, and seminoma (White et al., 2013). With
the advent of transgenic technology, though, zebrafish became a formidable tool for cancer
studies. Numerous transgenic zebrafish models have been created to model expression of
oncogenes resulting in a range of cancers, including melanoma, leukemia, lymphoma, rhab-
domyosarcoma, neuroblastoma, pancreatic, and hepatocellular carcinoma (Langenau et al.,
2003; Patton et al., 2005; Sabaawy et al., 2006; Dovey et al., 2009; Santoriello et al., 2010;
Liu and Leach, 2011; Nguyen et al., 2012; Zhu et al., 2012; Li et al., 2013).
In zebrafish, the liver is similarly comprised of hepatocytes, cholangiocytes, endothelial
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cells, Kupffer cells, and stellate cells; however, unlike its mammalian counterparts, hepato-
cytes are not arranged into hepatic lobules as the portal veins, hepatic arteries, and biliary
ducts are distributed throughout the liver in the zebrafish (Menke et al., 2011; Yao et al.,
2012). Hepatocytes in the zebrafish liver are instead centralized around biliary cells. The ze-
brafish is also uniquely advantageous for studying liver development since the embryonic liver
is not a site of hematopoiesis as it is in mammals, allowing for the study of developmental
defects without complications from anemia or early lethality.
1.3.2 Liver Development
The liver is derived from the anterior endoderm, which itself is one of three germ layers
established during gastrulation. In mice, cell fate studies showed three distinct domains of
hepatic progenitor cells within the developing foregut that converge to generate the epithelial
cells of the liver bud (Tremblay and Zaret, 2005). As the hepatic progenitor cells converge
and bud into the surrounding stroma, they receive induction signals from the adjacent devel-
oping heart and septum transversum mesenchyme (STM) (Si-Tayeb et al., 2010). Fibroblast
growth factor (FGF) family members FGF1 and FGF2 were found to be able to substitute for
cardiac mesoderm in the induction of hepatoycte gene expression programs, such as albumin
(Jung et al., 1999). From the STM, bone morphogenetic proteins (BMPs), activate genes
important for induction of hepatic specification in part by affecting the GATA4 transcrip-
tion factor (Rossi et al., 2001). In addition to FGF and BMP signaling, the WNT signaling
pathway plays a complex role in hepatic endoderm specification and hepatocyte expansion
(Si-Tayeb et al., 2010). Following specification of the hepatic endoderm, hematopoietically
expressed homeobox (HHEX), a homeodomain transcription factor, is expressed in the ven-
tral foregut endoderm and is the earliest known marker of the developing liver (Keng et al.,
2000; Martinez Barbera et al., 2000). Prospero homeobox protein 1 (PROX1), another
homeodomain transcription factor, is found in the hepatic bud and also promotes hepato-
blast specification (Sosa-Pineda et al., 2000). Other transcription factors, such as members
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Figure 1.3.2: (A) Hepatic progenitors are specified in the gut tub by 24 hpf. FoxA3 (purple)
is expressed in the endoderm, and hepatocyte precursors aggregate at the anterior. The liver
bud, marked by hhex (yellow), grows to the left of midline and expands outwardly at 48 hpf.
By 72 hpf, the hepatocyte marker lfabp (green) marks the formed liver. (B) Lateral and (C)
dorsal depictions of the expression of lfabp of the liver (green) at 72 hpf. Image courtesy of
Diane Saunders.
of the forkhead box A (FOXA), GATA-binding factor (GATA) and hepatocyte nuclear factor
(HNF) families, direct hepatic differentiation and control the onset of hepatic gene expression
during liver bud formation (Si-Tayeb et al., 2010).
In the zebrafish, liver development occurs much more rapidly as a fully functioning liver
is seen by 5 days post fertilization (dpf). Importantly, the same transcriptional networks and
molecular signaling are conserved between terrestrial vertebrates and zebrafish. In zebrafish,
liver development can be broken down into three stages: (1) specification, (2) differentiation,
and (3) outgrowth (Figure 1.3.2). In specification, liver progenitors in the anterior endoderm
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are first identifiable by hhex expression, and these hepatoblasts aggregate and appear as
a prominent bud to the left of the midline between 24-28 hours post fertilization (hpf).
These hepatic precursors also express prox1 and gata6. Experiments utilizing heat shock-
mediated expression of a dominant negative BMP receptor or FGF receptor in the zebrafish
resulted in decreased expression of hhex and prox1 in the liver region(Shin et al., 2007). In
addition, wnt2bb and adenomatous polyposis coli (APC ) zebrafish mutants demonstrated
defective hepatic specification(Goessling et al., 2008; Ober et al., 2006). Together, these
studies show that BMP, FGF, andWNT signaling are a conserved requirement in hepatoblast
specification.
Hepatocyte differentiation in the zebrafish begins around 34 hpf, when markers of hep-
atoblast maturation begin to be expressed, such as the copper-binding protein gene, ceulo-
plasmin (cp), followed by the selenoprotein P, plasma, 1b (sepp1b). However, it is not until
48 hpf that the liver begins to be fully differentiated as hepatocytes begin to express genes
indicative of mature hepatocyte function such as liver fatty acid binding protein (lfabp) and
group specific component (gc). The vascular network in the liver begins to develop between
55-60 hpf as endothelial cells begin their invasion into the liver. Simultaneously, biliary cells
in the liver begin to form, with cyotkeratin staining identifying the first cells between 50-60
hpf and biliary ducts by 70 hpf (North and Goessling, 2011). Proliferation accelerates as
the hepatocytes differentiate in the outgrowth phase with a resulting mature liver that has
three lobes (Menke et al., 2011; Yao et al., 2012).
1.3.3 Hippo Signaling and the Liver
In mammals, the initial studies linking the Hippo pathway with organ size control were
conducted in the postnatal mouse liver, where conditional activation of a nuclear localized
YAP mutant caused more than a three-fold increase in liver mass as a result of hepatocyte
hyperproliferation, and with continued YAP overexpression, progressed to hepatocellular
carcinoma (Camargo et al., 2007; Dong et al., 2007). Liver-specific deletions of upstream
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Hippo pathway members resulted in similar hepatomegaly and development of hepatocellular
carcinoma and cholangiocarcinoma (Lee et al., 2010; Benhamouche et al., 2010; Zhou et al.,
2009). Further supporting the potential of YAP to be oncogenic in the liver, YAP is amplified
and overexpressed in human hepatocellular carcinoma and cholangiocarcinoma (Zender et al.,
2006; Kim et al., 2013).
Studies, though, have been conflicting in the role of YAP on hepatocyte differentiation
and progenitor cells. In a conditional knockout model of YAP in the liver, loss of YAP led to
decreased hepatocyte survival as well as defects in biliary development (Zhang et al., 2010).
In a gain-of-function model, the conditional combined deletion of Hippo pathway members
MST1 and MST2 in the liver showed an increase in nuclear YAP as well as increased cel-
lular proliferation of both hepatocytes and oval cells, a poorly defined liver progenitor cell
population (Lu et al., 2010). Another study examined the conditional deletion of SAV1 in
the liver and found hyperproliferation of oval cells without a change in the proliferation of
hepatocytes (Lee et al., 2010). In the context of bile-acid induced liver injury, hyperprolif-
eration of hepatocytes and expansion of oval cells have been observed following increased
nuclear YAP localization(Anakk et al., 2013). More recently, it has been suggested that
activated YAP overexpression is able to directly dedifferentiate hepatocytes into progenitor
oval cells(Yimlamai et al., 2014). However, the role of YAP in embryonic liver development
has not been explored and could help elucidate its role in hepatocyte differentiation.
With the ability of YAP to induce rapid proliferation of hepatocytes, a major question
concerning how it is able to support rapid cell division remains to be answered. Intriguingly,
in heterozygous YAP mice, microarray analysis indicated that genes involved in metabolism
may be deregulated (Septer et al., 2012). This opens the question as to whether YAP can
can directly reprogram cellular metabolism to produce the necessary building blocks required
for cellular proliferation and organ growth.
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1.4 Overview of the Dissertation
In this dissertation, I examine the role of Yap in metabolically reprogramming cells for
anabolic synthesis in order to sustain rapid proliferation. In Chapter 2, I utilize transgenic
zebrafish that specifically express a constitutively active form of Yap in hepatocytes to show
that Yap drives hepatocyte proliferation and hepatomegaly in the zebrafish. I demonstrate
that Yap, in these transgenic livers, upregulates glutamine synthetase expression and activity
in order to drive nitrogen flux into de novo nucleotide biosynthesis. I also show that chemical
treatment with a glutamine synthetase chemical inhibitor reduces Yap-induced liver growth.
In Chapter 3, I describe the role of Yap in early liver development using yap knockout
zebrafish and heat shock inducible zebrafish that can modulate Yap transcriptional activity.
Here, I find that loss of Yap results in decreased glucose transporter expression and cellular
reprogramming of the carbon backbone of glucose into purine and pyrimidine synthesis in
vivo. In the final chapter, I discuss our conclusions and the current model of the role of Yap
in cellular metabolic reprogramming. I also discuss future directions and unknown questions
as to the role of Yap as a central regulator of organ growth.
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The Role of Yap in Glutamine
Metabolism During Liver Development
and Tumorigenesis
2.1 Abstract
The Hippo pathway has emerged as a master regulator of organ size and tumorigenesis. It is
unclear, however, how the Hippo pathway affects cellular metabolism to provide the energy
and cellular building blocks required for rapid cell growth. Here, we utilize transgenic ze-
brafish with liver-specific expression of the Hippo pathway effector Yap to demonstrate that
Yap promotes hepatomegaly, liver dysplasia and increased susceptibility to chemical hepato-
carcinogenesis. Transcriptomic and metabolomic profiling identified glutamine metabolism
as a predominant target of Yap. Yap activation enhances glutamine synthetase (Glul) ex-
pression and activity. This results in elevated steady-state levels of glutamine and enhanced
nitrogen flux into de novo purine and pyrimidine biosynthesis. In vitro studies in human
liver cancer cells identify Glul as a direct target of Yap. Yap-mediated activation of Glul
is required for rapid cell and organ growth, as Glul knockdown or intervention studies with
the Glul inhibitor methionine sulfoximine diminish Glul activity, inhibit nitrogen flux into
nucleotide biosynthesis and suppress liver growth observed in Yap transgenics. We conclude
that Yap regulates Glul expression and reprograms nitrogen metabolism to enhance liver
growth during development and tumorigenesis. Our findings demonstrate that Yap inte-
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grates the anabolic demands of rapid cell proliferation by increasing the flux of glutamine
into nucleotide biosynthesis.
2.2 Introduction
Many signaling pathways have been identified to govern liver growth during organ develop-
ment and tumor formation. It is often unclear, however, how these signals provide energy
and cellular building blocks to enable rapid cell division and organ growth. The Hippo sig-
naling pathway has emerged as an evolutionarily conserved master regulator of organ size
and tissue growth (Yu and Guan, 2013; Piccolo et al., 2014). The Hippo kinase cascade
regulates the transcriptional co-activator Yap that binds the Tead family of transcription
factors to enhance cell proliferation, inhibit cell death and alter cell fate (Pan, 2010; Yu
et al., 2015). The Hippo pathway is frequently perturbed in human cancer(Harvey et al.,
2013). Recent studies have shown that many oncogenic pathways including Wnt (Imajo
et al., 2012; Rosenbluh et al., 2012; Azzolin et al., 2012), Ras (Zhang et al., 2014; Shao
et al., 2014; Kapoor et al., 2014), PI3K/mTOR (Liang et al., 2014; Tumaneng et al., 2012b),
TGFβ (Alarcon et al., 2009; Varelas et al., 2010b; Fujii et al., 2012), Hedgehog (Fernan-
dez et al., 2009; Huang and Kalderon, 2014; Amoyel et al., 2014), Rb (Nicolay et al., 2010;
Tschop et al., 2011; Ehmer et al., 2014) and LKB1 (Mohseni et al., 2014; Nguyen et al.,
2013) feed into the Hippo pathway and sustain growth in a Yap-dependent manner. While
many upstream regulators of Yap are now well defined, the molecular mechanisms by which
Yap target genes enable rapid cell proliferation to modulate organ size remain elusive.
Altered cellular metabolism is a hallmark of cancer cells (Hanahan and Weinberg, 2011).
Until recently, a number of studies had focused attention on the alternate means by which
cancer cells produce ATP, including aerobic glycolysis (Vander Heiden et al., 2009) or the
anaplerotic use of alternate fuel sources such as glutamine (Deberardinis et al., 2008; Hensley
et al., 2013). However, new findings have elaborated on mechanisms by which oncogenic
23
Chapter 2. The Role of Yap in Glutamine Metabolism During Liver Development and
Tumorigenesis
pathways, such as mTOR, enhance de novo synthesis of building blocks and macromolecules
required for cell growth (Dibble and Manning, 2013). Despite the substantial progress in
our understanding of metabolic reprogramming in cancer, it is unknown whether the Hippo
pathway can rewire cellular metabolism to match the demands for rapid cell growth.
Here, we investigate transgenic zebrafish expressing activated Yap in the liver that develop
hepatomegaly and are prone to liver tumor formation. Transcriptomic and metabolomic
analyses reveal that Yap induces glutamine synthase (Glul), to elevate glutamine flux into
anabolic processes, particularly nucleotide synthesis. We demonstrate that Yap-dependent
regulation of Glul is conserved in humans. Finally, we identify Glul as a primary target of
Yap activation, which is required for maximal proliferation during the development of hep-
atomegaly. Treatment studies in larval and adult zebrafish demonstrate that Glul inhibition
diminishes Yap-induced liver growth. Our studies define a new role of Yap to rewire cellular
metabolism to provide the anabolic requirements for rapid cell growth and illustrate the
therapeutic promise of targeting Yap-driven alterations in metabolism.
2.3 Materials and Methods
Zebrafish Husbandry
Zebrafish were maintained according to institutional animal care and use committee (IACUC-
BIDMC) protocols. Lines used in this study include WT (AB) and Tg(-2.8fabp10a:eGFP)as3
as previously described (Her et al., 2003b,a). Tg(−2.8fabp10:Yap1S87A; −0.8cryaa:Venus,
abbreviated lf:Yap) express a constitutively activate form of Yap (Yap1S87A) driven by the
hepatocyte-specific promoter fabp10a. This line also contained the selection marker Venus,
driven by the cryaa promoter, which produced green fluorescence in the lens of the eye.
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Chemical Exposure
Embryos and adult zebrafish were exposed to methionine sulfoximine (MSO, 1 mM) and
dimethylbenzanthracene (DMBA, 5 ppm) as described. Where necessary, chemicals were
dissolved in DMSO. Chemicals were obtained from Sigma-Aldrich (St. Louis, MO, USA).
Morpholino Injection
Morpholinos (MO) (GeneTools, PhiloMath, OR, USA) designed against exon2-intron2 splice
sites of glula (5’- ATAGTTCAAGTCCAGCTTACCTTCA -3’) and glulb (5’- AATACAA-
CAACTACCTTCAACAGAT -3’) or mismatched controls glula-MM (5’- ATAcTTaAAcTC-
CAcCTTAaCTTCA -3’) and glulb-MM (5’- AATAaAAaAACTACaTTCAAaAcAT -3’) were
injected into Tg(-2.8fabp10a:eGFP) and Tg(-2.8fabp10a:eGFP); lf:Yap embryos at the one-
cell-stage.
Fluorescence Microscopy
Fluorescent liver reporter Tg(-2.8fabp10a:eGFP) embryos were put under anesthesia with
0.04 mg/ml Tricaine-S and microscopy was performed. Embryos were imaged using a Zeiss
Discovery V8/Axio Cam MRC with the Axiovision software suite (Carl Zeiss). Lightsheet
microscopy was performed using a Zeiss Lightsheet Z.1 at the Harvard Center for Biological
Imaging (HCBI) core and analyzed using FIJI (NIH) as previously described (Weber et al.,
2014; Schindelin et al., 2012).
Histology
Paraformaldehyde (PFA)-fixed embryos, fish or mice livers were paraffin-embedded, cut into
serial sections and stained with Hematoxylin and Eosin (H&E) using standard techniques.
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FACS Analysis
Fluorescent liver reporter Tg(-2.8fabp10a:eGFP) embryos were dissociated by enzymatic
disaggregation in TrypLETM Express (Invitrogen, CO, USA) combined with manual dis-
ruption. Upon addition of DMEM with 10% FCS, the cells were strained through a 35 μM
nylon mesh and then analyzed using a BD FACSAria II flow cytometer (BD Biosciences,
San Jose, CA, USA).
DMBA-induced carcinogenesis
WT and lf:Yap transgenic fry were exposed to 5 ppm DMBA dissolved in DMSO for 24 hr
at 3, 4 and 5 weeks of age. Following exposure fry were rinsed several times in aquarium
water before being returned to the aquarium tanks. Fish were monitored closely for tumor
development over the subsequent 6 months.
RNA Transcriptomic Analysis
Livers were isolated from adult WT and lf:Yap transgenic adults and RNA was extracted
in Trizol (Life Technologies) and purified using the RNease Mini Kit (Qiagen) according to
the manufacturers instructions. RNA quality was checked using an Agilent Bioanalyzer and
sequenced using an Illumina platform. polyA sequence data was annotated on a genomic
reference (ZV9) to identify differentially affected genes (Collins et al., 2012).
qPCR analysis
RNA was isolated from pooled zebrafish embryos or isolated livers using Trizol (Life Tech-
nologies). Following DNAse treatment, cDNA synthesis was performed using the SuperScript
III First-Strand Synthesis kit (Life Technologies). Quantitative RT-PCR was performed on
biological triplicates using an iCycler (BioRad) with iQ SYBR green (BioRad). Gene ex-
pression was analyzed with Ef1α as the reference gene. Primer sequences can be found in
Table 2.3.1.
26
Chapter 2. The Role of Yap in Glutamine Metabolism During Liver Development and
Tumorigenesis
Table 2.3.1: qPCR Primer Sequences
Gene Forward Primer Reverse Primer
ef1α GCGTCATCAAGAGCGTTGAG TTGGAACGGTGTGATTGAGG
ctgfa CTACGGCTCCCCAAGTAACC TCCACTGCGGTACACCATTC
cyr61 ACAAGCTGCAACCTACCACT AGAGTATTCATTCTACTCACACTCA
amotl2b TCCCAGCACAACAGACTTCC CCGTTTGTCCCTCTAGCTCC
glula ATGGTGGACTGAAATGTATTGAGG AATGTTGGAGGTTTCATGGTGG
glulb GCCCGCTTCCTCCTACACA CTCCTCAATATGCTTCAAACCTCC
axin2 GGACACTTCAAGGAACAACTAC CCTCATACATTGGCAGAACTG
cyclinD1 GGAACTGCTGGCGCTTAAATA GACTTGCGAGAGGAAGTTGG
ChIP analysis
Chromatin Immunoprecipitation was performed essentially as previously described (Galli
et al., 2012). Briefly, cells were cross-linked in 1% formaldehyde for 10 min at room tem-
perature after which the reaction was stopped by addition of 0.125M glycine. Cells were
lysed and harvested in ChIP buffer (100 mM Tris at pH 8.6, 0.3% SDS, 1.7% Triton X-100,
and 5 mM EDTA) and the chromatin disrupted by sonication using a Diagenode Bioruptor
sonicator UCD-200 to obtain fragments of average 200-500 bp in size. Suitable amounts
of chromatin were incubated with specific antibodies overnight. Antibodies used were IgG
(Sigma, I8140), Yap (a kind gift of Joseph Avruch, MGH, Boston), Tead4 (Abcam Ab58310).
Immunoprecipitated complexes were recovered on Protein-A/G agarose beads (Pierce) and,
after extensive washes, DNA was recovered by reverse crosslinking and purification using
QIAquick PCR purification kit (QIAGEN).
Luciferase assay
HEK293 cells were cotransfected with glutamine synthetase reporter constructs (van der Vos
et al., 2012), the Renilla plasmid, and pCMV-EGFP, pCMV-Yap-S127A (Addgene, #17794),
or pCMV-Yap-S94A. Cells were harvested 48 hr later using the Dual-Glo Luciferase Assay
System (Promega) and assayed according to the manufacturer’s directions.
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Cell culture and lentiviral infection
HEK293, HepG2 and Huh7 cells were grown in high glucose Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal bovine serum and maintained at 37 °C in a humidified
atmosphere with 5% CO2. HEK293T cells were transiently transfected with polyethylen-
imine (PEI) gene transfer reagent (Boussif et al., 1995) in its 25-kDa linear form (Poly-
sciences, Warrington, PA). pLKO.1 plasmid constructs were co-transfected in HEK293T cells
with packaging vectors pCMV-Δ8.2 and pCMV-VSVG using polyethyleimine. Two days
post-transfection, virus-containing media was harvested, 5 μg of Polybrene added, passed
through a 0.45 μM filter, and used to infect target cells. Target cells at approximately 70%
confluence were infected for 24 hr followed by selection in 2 μg/mL puromycin for 48 hr prior
to stimulation and cell lysis.
Immunoblot analysis
Cultured cells were collected and lysates were prepared using RIPA buffer. Lysates were
resolved by SDS-PAGE and electrophoretically transferred onto nitrocellulose. Membranes
were probed with anti-Yap (AbCam), anti-Glul (Cell Signaling) or a overnight and detected
with secondary antibody conjugated with HRP. Antibody complexes were visualized by
enhanced chemiluminescence using X-ray film.
Steady-state metabolomics analysis
Livers were isolated from adult WT and lf:Yap transgenic adults and a methanol extraction
was performed. Polar metabolites were isolated and enriched using the methodology outlined
by Yuan et al (Yuan et al., 2012). Polar metabolites were quantified using selected reaction
monitoring on a 5500 QTRAP hybrid triple quadrupole mass spectrometer.
28
Chapter 2. The Role of Yap in Glutamine Metabolism During Liver Development and
Tumorigenesis
Glul activity assay
Glul activity was assayed using the γ-glutamyltransferase assay as previously described
(Deuel et al., 1978). Briefly, WT and lf:Yap transgenic embryos or adult livers were lysed
in 50mM imidazole. Lysates were run on micro bio-spin gel p-6 columns (BioRad) and
protein quantification was performed using the DCTM assay (BioRad). Lysates were incu-
bated in activity buffer (50 mM imidazole, 50 mM L-glutamine, 25 mM hydroxylamine, 25
mM sodium arsenate, 2mM manganese chloride, 0.16 mM adenosine diphosphate) at 27 °C
for 30 min. The reactions were quenched in stop solution (2.42% iron chloride and 1.45%
trichloroacetic acid in 1.82 N hydrochloric acid). Absorbance was read at 520 nm and a
calibration curve of glutamyl-γ-hydroxamate (Sigma) was used to calculate nmol of product
formed.
Determination of ammonia excretion rate
The rate of ammonia excretion was determined by placing individual fish into small water
containers and monitoring ammonia buildup over time using methods previously established
(Bucking et al., 2013) and an ammonia detection kit (Biovision Inc.) according to the
manufacturers instructions.
Analysis of 15NH4Cl flux in liver lysates
Ammonia incorporation into nucleotide precursors was measured using adaptations to pre-
viously established methods (Skaper et al., 1978; Monks et al., 1985). Briefly, livers were
isolated from adult WT and lf:Yap transgenic adults and liver homogenates were prepared
in lysis buffer (100mM NaCl, 25mM Imidazole, 25mM HEPES, 1mM MgCl2, 1mM MnCl2,
0.1mM KCl and 1% NP-40 pH 7.4 supplemented with Complete protease inhibitors (Roche)).
Liver homogenates (90 μl) containing the same amount of protein were incubated a reaction
cocktail (10 μl) containing 10 mM 15NH4Cl (Cambridge Isotopes Laboratories, Inc.), 10 mM
ATP and 10 mM sodium glutamate and incubated at 37 °C for 20 min before the reaction was
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quenched in 80% Methanol (900 μl). Polar metabolites were enriched using the methodology
outlined by Yuan et al. (Yuan et al., 2012) and quantified using selected reaction monitoring
on a 5500 QTRAP hybrid triple quadrupole mass spectrometer using a protocol to detect
15N-labelled isotopomers of nucleotide precursors.
15N-Spirulina feeding protocol
15N-labelled Spirulina (98%) (Cambridge Isotopes Laboratories, Inc.) gels containing 50
mg/ml 15N-labelled Spirulina, 5 mg/ml Gemma Micro 300 (Skretting) and 1% agar were
aliquoted into 30 μl pellets. Individual WT and lf:Yap transgenic adults were given a 15N-
labelled Spirulina gel pellet twice a week over a 4 week period.
Analysis of 15N-Spirulina nutritional flux into genomic DNA
Livers were isolated from adult WT and lf:Yap transgenic adults and genomic DNA was
isolated using Quick-gDNA™ MiniPrep (Zymo Research) according to the manufacturers
instructions and re-purified by sodium acetate precipitation. DNA from 15N-labeled spirulina
and unlabeled spirulina was extracted as previously described (Morin et al., 2010). Purified
DNA was quantified with PicoGreen (Life Technologies), and 100 ng of DNA was treated
with DNA Degradase Plus (Zymo Research) for 24 hours. Completion of DNAse digestion
was measured by PicoGreen quantification. Hydrolyzed nucleotides were enriched using
the methodology outlined by Yuan et al. (Yuan et al., 2012) and quantified using selected
reaction monitoring on a 5500 QTRAP hybrid triple quadrupole mass spectrometer using a
protocol to detect 15N-labelled isotopomers of nucleotides.
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Figure 2.4.1: Schematic of lf:Yap construct. Diagram of the construct used to generate
transgenic fish with hepatocyte-specific expression of Yap1S87A, abbreviated to lf:Yap.
2.4 Results
Hepatocyte-specific overexpression of Yap causes hepatomegaly and accelerates
DMBA-induced liver tumor formation
To address the impact of Yap activation on liver growth in the zebrafish embryo, we gen-
erated transgenic zebrafish Tg(-2.8fabp10:Yap1S87A) (lf:Yap) with hepatocyte-specific ex-
pression of a constitutively active form of Yap, homologous to human YAP1S127A (Figure
2.4.1). Liver development was visualized using an established hepatocyte reporter line, Tg(-
2.8fabp10:eGFP), referred to as lf:GFP. By 5 dpf, which is within 2 days of transgene in-
duction, lf:Yap;lf:GFP fish exhibit a 36% increased liver area (Figure 2.4.2 A,B) compared
to their wild type (WT) siblings. Single-plane illumination confocal microscopy was per-
formed to produce a 3D-rendering of WT and lf:Yap transgenic livers and this confirmed
liver enlargement and preservation of gross architectural features of the bi-lobed embryonic
liver (Figure 2.4.2 C,D). Histological and FACS analysis revealed that increased liver size in
the transgenic animals is accompanied by hepatocyte hyperproliferation without significant
increase in liver cell size (Figures 2.4.2 E,F). Increased liver size was maintained in lf:Yap
fish into adulthood at 16 weeks post fertilization (wpf) (Figure 2.4.3 A,B): liver-to-body
weight ratio was two-fold increased in lf:Yap transgenics (Figure 2.4.3 C). Adult lf:Yap liv-
ers are hyperplastic with increased cellularity and a significant increase in cell proliferation,
increased bile duct density and a decreased amount of glycogen deposition (Figure 2.4.3 D).
These data demonstrate that Yap induces hepatomegaly and promotes liver hyperplasia in
zebrafish.
Liver hyperplasia did not spontaneously progress to frank cancer even in 2 year-old fish
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Figure 2.4.2: Hepatocyte-specific overexpression of Yap causes embryonic hep-
atomegaly. (A) Fluorescence microscopic analysis of hepatomegaly in lf:Yap;lf:GFP com-
pound transgenic embryos at 5 dpf. (B) Quantitative analysis of fluorescent liver area in
WT and lf:Yap transgenic embryos at 5 dpf. (C) Confocal tomography of liver morphology
in WT and lf:Yap transgenic embryos at 5 dpf. (D) Quantitative analysis of liver volume in
WT and lf:Yap transgenic embryos at 5 dpf. (E) Histological evaluation of liver morphology
in WT and lf:Yap transgenic embryos at 5 dpf. (F) FACS analysis of the percentage of
differentiated hepatocytes in WT and lf:Yap transgenic embryos at 10 dpf. n > 17, p <
0.0001.
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Figure 2.4.3: Hepatocyte-specific overexpression of Yap causes adult hep-
atomegaly. (A) Fluorescence microscopic analysis of hepatomegaly in dissected lf:Yap
transgenics at 12 weeks post fertilization (wpf). (B) Timecourse of hepatomegaly during
early adulthood as determined by quantification of fluorescent liver area. (C) Quantitative
determination of hepatomegaly in WT and lf:Yap as determined by liver:body weight ratio.
n = 6. p ≤ 0.01. (D) H&E staining of histological sections from liver of WT and lf:Yap
transgenics at low (10x) and high magnification (25x). Periodic-acid Schiff (PAS) stain for
hepatic glycogen (pink inclusions) in liver sections from WT and lf:Yap transgenics. Bile
duct morphogenesis (2F11) in liver sections from WT and lf:Yap transgenics.
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Figure 2.4.4: Yap overexpression accelerates DMBA-induced liver tumor forma-
tion. (A) Schematic illustrating the exposure of zebrafish to the chemical carcinogen DMBA.
(B) Kaplan-Meier survival plot showing tumor-free survival of WT and lf:Yap transgenics
exposed to DMBA. n > 35 fish, p < 0.0001 by Log rank Mantel-Cox test. (C) Fluorescence
microscopy examination of gross liver morphology of WT and lf:Yap transgenic tumors fol-
lowing dissection. (D) Histological evaluation (H&E stain) of liver sections in WT and lf:Yap
transgenics harboring tumors.
(data not shown). To examine whether Yap predisposes to liver tumor formation, WT and
lf:Yap transgenics were exposed to the carcinogen dimethylbenzanthracene (DMBA) (Figure
2.4.4 A). lf:Yap transgenics formed liver tumors earlier and with greater frequency than
their wild type siblings (Figure 2.4.4 B). Tumors were evident as abdominal enlargements
showed liver masses taking up the entirety of the abdominal cavity (Figures 2.4.4 C, D).
Examination by immunohistochemistry revealed a spectrum of liver cancer subtypes ranging
from hepatocellular carcinoma (HCC) to cholangiocarcinoma (CCA) with features of peliosis
hepatis, fibrosis, sarcomatoid cytology and ascites (Figure 2.4.5 and Table 2.4.1). These data
demonstrate that Yap is a potent oncogene that can accelerate and exacerbate chemically
induced hepatocarcinogenesis.
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Figure 2.4.5: Tumor heterogeneity in lf:Yap transgenics exposed to DMBA. lf:Yap
tumors include Hepatocellular carcinoma (HCC), Sarcamatoid HCC, Peliosis hepatis HCC
and Cholangiocarcinoma (CCA).
Table 2.4.1: Tumor subtype frequency in DMBA exposed WT and lf:Yap trans-
genics. Table illustrating the incidence of fibrosis, glycogen, sarcomatoid cytology, peliosis
hepatis and ascites in DMBA-induced liver tumors.
Tumor 
subtype Fibrosis 
Glycogen 
poor 
Sarcomatoid 
cytology 
Peliosis 
hepatis Ascites 
WT 
HCC 50% (2/4) 100% (4/4) 25% (1/4) 25% (1/4) 0% (0/4) 
CCA 100% (1/1) 100% (1/1) N/A N/A 0% (0/1) 
YapS87A 
HCC 47% (9/19) 84% (16/19) 21% (4/19) 58% (11/19) 32% (6/19) 
CCA 100% (4/4) 100% (4/4) N/A N/A 25% (1/4) 
35
Chapter 2. The Role of Yap in Glutamine Metabolism During Liver Development and
Tumorigenesis
Yap alters expression of metabolism-related genes and enhances Glul expression
To identify downstream pathways responsible for Yap-driven liver hyperplasia, we performed
transcriptional profiling in WT and lf:Yap transgenic adult livers, revealing a large number
of differentially expressed genes (Figure 2.4.6 A). Gene set enrichment analysis (GSEA)
confirmed consistency with a previously published mammalian Hippo signature (Figure 2.4.7
A) (Cordenonsi et al., 2011), including upregulation of the bona fide Yap target genes amotl2,
ctgf and cyr61 (Figure 2.4.6 C). Intriguingly, gene ontology (GO) analysis revealed that 60%
of the top 20 biological processes upregulated by Yap were related to metabolism (Figure
2.4.6 B). Amongst the most differentially upregulated genes were glutamine synthetase (Glul)
orthologs Glula and Glulb (Figure 2.4.6 C), which play a key role in nitrogen assimilation in
the liver. Quantitative PCR (qPCR) verified induction of ctgf, cyr61, amotl2, glula and glulb
in lf:Yap livers (Figure 2.4.6 D,E). While Glul expression has been reported to be regulated
by Wnt activity, no activation of the Wnt target genes cyclinD1, axin2 and cd44 was seen
in the lf:Yap transgenics (Figure 2.4.7 B,C).
Yap transcriptionally upregulates Glul and is evolutionarily conserved
Chromatin immunoprecipitation (ChIP) was performed to determine whether Yap transcrip-
tionally regulates Glul directly. We found Yap was enriched at the promoter region of the
actively transcribed gene glula as avidly as ctgf (Figures 2.4.8 A,B). To determine whether
Yap-dependent regulation of Glul is evolutionarily conserved in humans, a luciferase re-
porter assay was utilized in HEK293 cells. This demonstrated that a constitutively active
form of human Yap (YapS127A) activates Glul expression, whereas a Yap mutant lacking the
ability to co-activate Tead (YapS94A) did not induce Glul (Figure 2.4.8 C). Promoter frag-
ment analysis revealed that several promoter regions contributed to the total Yap-induced
increase in activity (Figure 2.4.9). ChIP analysis in HepG2 cells revealed Yap occupation
of the Glul promoter in the region associated with luciferase activation (Figure 2.4.8 D).
shRNA-mediated knockdown of Yap in HepG2 liver cancer cell lines led to reduction in Glul
36
Chapter 2. The Role of Yap in Glutamine Metabolism During Liver Development and
Tumorigenesis
gl
ul
a
gl
ul
b
0.0
2.5
5.0
7.5
10.0
R
e
la
ti
v
e
 e
x
p
re
s
s
io
n
 
(F
o
ld
 C
h
a
n
g
e
)
qPCR Metabolism Targets
WT
lf:Yap
*
*
ct
gf
cy
r6
1
am
ot
l2
b
0
5
10
15
20
25
qPCR Hippo Targets
R
e
la
ti
v
e
 e
x
p
re
s
s
io
n
 
(F
o
ld
 C
h
a
n
g
e
)
WT
lf:Yap
*
**
***
!!
!Top 20 Upregulated Biological Processes 
 
!!
!! !!
!! GO Accession  Biological processes upregulated p.val !!
!! GO:0006865  Amino acid transport 7.54351E-05 !!
!! GO:0006820  Anion transport 0.000140675 !!
!! GO:0070482  Response to oxygen levels 0.000197681 !!
!! GO:0036293  Response to decreased oxygen levels 0.000258205 !!
!! GO:0046460 Neutral lipid biosynthetic process 0.000586188 !!
!! GO:0046463 Acylglycerol biosynthetic process 0.000586188 !!
!! GO:0019432  Triglyceride biosynthetic process 0.000715268 !!
!! GO:0001666 Response to hypoxia 0.000727509 !!
!! GO:0015711 Organic anion transport 0.000765133 !!
!! GO:0006638 Neutral lipid metabolic process 0.000858847 !!
!! GO:0006639 Acylglycerol metabolic process 0.000858847 !!
!! GO:0034330 Cell junction organization 0.00092631 !!
!! GO:0045216 Cell-cell junction organization 0.000963116 !!
!! GO:0007009  Plasma membrane organization 0.001063152 !!
!! GO:0006641 Triglyceride metabolic process 0.001067452 !!
!! GO:0006814 Sodium ion transport 0.001214601 !!
!! GO:0034333 Adherens junction assembly 0.001504782 !!
!! GO:0001944 Vasculature development 0.001632558 !!
!! GO:0034329  Cell junction assembly 0.002031531 !!
!! GO:0007044 Cell-substrate junction assembly 0.002370116 !!
!! !! !! !! !!
A B C 
D E 
Figure 2.4.6: Yap alters expression of metabolism-related genes and enhances Glul
expression. (A) RNA-seq analysis identifies differential gene expression between dissected
WT and lf:Yap transgenic livers. (B) Gene ontology (GO) analysis of the top 20 biological
processes upregulated by Yap. Biological processes related to metabolism are highlighted in
red. (C) Heat Map analysis of RNA-seq data illustrates the induction of Yap target genes
(ctfg, amotl2b, cyr61 ) and genes related to nitrogen metabolism (glula, glulb). (D) qPCR
validation of Yap target gene expression in dissected WT and lf:Yap transgenic livers. (E)
qPCR validation of Glul induction in dissected WT and lf:Yap transgenic livers. mean ±
S.E.M, biological triplicates, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
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Figure 2.4.7: Yap expression in the zebrafish demonstrates features of a Hippo
target gene signature without Wnt features. (A) Gene set enrichment (GSEA) derived
from RNA-seq of WT and lf:Yap transgenic livers identifies a conserved Yap target gene
signature. (B) RNA-seq analysis of the Wnt target genes CyclinD1, Axin2, Cd44 in dissected
WT and lf:Yap transgenic livers. (C) qPCR validation of Wnt target genes axin2 and
cyclinD1 in dissected WT and lf:Yap transgenic livers. Data are represented as mean ±
S.E.M, biological triplicates, N.S. = not significant.
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Figure 2.4.8: Yap transcriptionally upregulates Glul and is evolutionarily con-
served. (A) Chromatin Immunoprecipitation (ChIP)-qPCR analysis of Yap enrichment at
Glula promoter in dissected WT and lf:Yap transgenic livers. (B) ChIP-qPCR analysis of
transcriptional activity (H3K27ac) at the Glula promoter in dissected WT and lf:Yap trans-
genic livers. (C) Luciferase Glul reporter assay in cultured HEK293 cells expressing GFP,
Yap1S127A or Yap1S94A, n = 3. (D) ChIP-qPCR analysis of Yao and Tead4 enrichment at
the Glul promoter in HepG2 cells.
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Figure 2.4.9: Luciferase reporter assay shows Glul promoter is directly regu-
lated by Yap. Luciferase Glul reporter assay using truncated promoter constructs were
co-transfected into HEK293 cells with GFP, Yap or Yap1S127A, n = 3.
expression (Figure 2.4.10 A). As in zebrafish, β-catenin levels did not change, and expression
of Wnt target genes was not affected (Figure 2.4.10 A). Regions of hepatocellular carcinomas
with high Glul expression also demonstrated high nuclear expression of Yap (Figure 2.4.10
B). Together, these studies demonstrate that the regulation of Glul by Yap is evolutionarily
conserved in humans.
Yap reprograms nitrogen metabolism by enhancing Glul-dependent anabolic as-
similation of ammonia for de novo nucleotide biosynthesis
To examine the effect of Yap expression on cellular metabolism, polar metabolomics by LC-
MS on isolated adult livers determined distinct metabolite profiles between transgenic lf:Yap
and WT livers. Metabolite clustergram analysis revealed regulation of many metabolite
steady-state levels (Figure 2.4.11 A), including enrichment of metabolites associated with
protein biosynthesis, purine metabolism and pyrimidine metabolism (Figure 2.4.11 B). lf:Yap
transgenic livers had a steady-state concentration of glutamine that was twice as much as
WT livers (Figure 2.4.11 C). Glul enzyme activity in lf:Yap transgenic liver homogenate was
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Figure 2.4.10: Glul expression is decreased in HepG2 cells with knockdown of Yap.
(A) Immunoblot analysis of Glul, Yap and β-catenin expression in HepG2 cells infected with
shYap retrovirus. (B) Immunohistochemical staining of Yap and Glul in Tissue Microarray
(TMA) sections derived from human HCC.
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Figure 2.4.11: Yap reprograms nitrogen metabolism by enhancing Glul acitivity.
(A) Clustergram analysis of polar metabolite abundance from dissected WT and lf:Yap
transgenic livers as determined by LC-MS/MS selected reaction monitoring (SRM) analysis.
(B) Metabolite Set Enrichment of polar metabolites from WT and lf:Yap transgenic livers
as determined by SRM analysis. (C) Steady state abundance of glutamine in WT and lf:Yap
transgenic livers as determined by SRM analysis. (D) Enzymatic assay of glutamine synthase
activity in dissected WT and lf:Yap transgenic livers. n = 3, p ≤ 0.001.
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Figure 2.4.12: Immunohistochemical detection of Glul. Glul expression in WT, lf:Yap
transgenic livers and DMBA-induced lf:Yap liver tumors.
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Figure 2.4.13: Ammonia excretion rates and urea abundance in individual WT and
lf:Yap transgenics. (A) Ammonia excretion rates in individual WT and lf:Yap transgenics.
(B) Steady state abundance of urea in WT and lf:Yap transgenic livers as determined by
SRM analysis.
increased 10-fold compared to WT (Figure 2.4.11 D). Consequently, immunohistochemistry
demonstrated uniform Glul overexpression in lf:Yap transgenic hepatocytes (Figure 2.4.12).
Glul expression was also elevated, but heterogeneously expressed in Yap-driven liver tumors
(Figure 2.4.12). To demonstrate changes in ammonia assimilation on the organism level,
the rate of ammonia excretion in adult zebrafish was measured in an in vivo assay, reveal-
ing decreased ammonia excretion rates in lf:Yap transgenic fish, consistent with nitrogen
retention (Figure 2.4.13 A). Similarly, metabolomics analysis revealed that lf:Yap transgenic
livers contained decreased steady-state levels of urea compared with WT (Figure 2.4.13 B).
To more precisely determine the fate of ammonia in lf:Yap transgenics livers overexpressing
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Figure 2.4.14: Yap reprograms15NH4Cl flux in liver lysates. (A) Scheme to monitor
the flux of 15NH4Cl in the presence or absence of MSO in liver lysates from WT and lf:Yap
transgenics. (B) Percentage of 15N-labelled Guanosine isotopomers in WT and lf:Yap trans-
genic liver lysates following ammonia assimilation in the presence or absence or MSO. (C)
Percentage of 15N-labelled Cytosine isotopomers in WT and lf:Yap transgenic liver lysates
following ammonia assimilation in the presence or absence or MSO.
Glul, extracted zebrafish liver were briefly incubated with 15N-labelled NH4Cl and ATP in
the presence or absence of the Glul inhibitor, methionine sulfoximine (MSO) (Figure 2.4.14
A). Glutamine is required for de novo nucleotide biosynthesis as it provides the nitrogen
atoms present on both purines and pyrimidines. Incorporation of 15N into nucleotide pre-
cursors was monitored by LC-MS, revealing that 15N-labelled isotopomers of Guanosine and
Cytosine, derived from 15N-labelled glutamine, were increased in the lf:Yap liver lysates and
this was inhibited in the presence of MSO (Figure 2.4.14 B,C). Altogether, these results
demonstrate that Yap reprograms nitrogen metabolism by activating Glul and promoting
the assimilation of ammonia via glutamine into precursors for nucleotide biosynthesis.
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Elevated Glul activity contributes to Yap-induced hepatomegaly
Given the dramatic impact of Yap on Glul expression and activity and the subsequent
metabolic changes, the requirement of Glul for mediating Yap-induced rapid liver growth
was examined utilizing genetic knockdown of Glula and Glulb (Figure 2.4.15 A,B). Yap-
induced increase in liver size at 120 hpf was partially mitigated in combined Glula/Glulb
morphants (Figure 2.4.16 A). Quantification of liver size confirmed that Glula/Glulb knock-
down significantly inhibited Yap-driven embryonic hepatomegaly (Figure 2.4.16 B, n > 34, p
= 0.0237). To complement these studies and to demonstrate potential therapeutic implica-
tions, embryos were exposed to MSO during the outgrowth phase of liver development from
3-5 dpf. MSO effectively inhibited Glul activity in whole larvae extracts (Figure 2.4.15 C)
and significantly inhibited Yap-driven hepatomegaly (Figure 2.4.16 C, n > 88, p = 0.0215).
Importantly, both Glula/Glulb knockdown and MSO treatment had no effect on liver size
or morphology in WT embryos (Figure 2.4.16 A,B,C). Together, these studies suggest that
Glul is conditionally required for the rapid cell proliferation leading to hepatomegaly in Yap
transgenics.
Yap reprograms nutritional nitrogen flux into nucleotide biosynthesis in a Glul-
dependent manner to support liver growth
The steady-state metabolomics data indicated that Yap altered nitrogen metabolism, but
it did not define how nitrogen is being utilized to contribute to accelerated cell growth. To
examine the fate of the increased glutamine present in the lf:Yap transgenics we developed
a novel feeding methodology to enable metabolic flux analysis. 15N-labelled Spirulina gel
pellets were prepared to provide fish with a defined and consistent amount of 15N-labelled
nutrition. Individual WT and lf:Yap transgenic fish were fed twice a week and maintained
in the presence or absence of MSO (twice a week for 48 hr) for 4 weeks (Figure 2.4.17 A).
Liver DNA was extracted and hydrolyzed into nucleotides for analysis (Figure 2.4.17 B).
lf:Yap transgenic livers contained a significantly higher amount of 15N-labelled nucleotides
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Figure 2.4.15: Validation of morpholinos and glutamine synthetase inhibition. Mor-
pholinos targeting splice sites in (A) glula and (B) glulb were validated by RT-PCR with
increasing amounts of morpholino. Ef1α was used as a control. MW = 100 bp ladder, Arrow
indicates expected spliced product, Arrowheads indicate splice variants. (C) Glul activity in
WT and lf:Yap embryonic extracts derived from embryos exposed to MSO from 3-5 dpf.
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Figure 2.4.16: Elevated Glutamine synthase activity contributes to Yap-induced
hepatomegaly. (A) Morpholino knockdown of Glula/b in WT and lf:Yap embryos showed
a decrease in Yap-induced hepatomegaly as determined by fluorescence microscopy at 5 dpf.
(B) Quantitative analysis of the effect of Glula/b morpholino knockdown on liver size. (C)
Quantitative analysis of the effect of MSO treatment from 3-5 dpf on liver size as determined
by fluorescence microscopy. p < 0.05.
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Figure 2.4.17: Yap reprograms nutritional nitrogen flux into nucleotide biosynthe-
sis in a Glul-dependent manner to support liver growth. (A) Scheme describing the
long-term 15N-Spirulina feeding studies in adult fish. (B) 15N flux analysis of deoxyguano-
sine isotopomers derived from hydrolyzed genomic DNA of liver and spirulina as determined
by LC-MS. (C) Abundance of 15N-labelled nucleotide (Deoxyinosine, Deoxyadenosine and
Deoxyguanosine) isotopomers (M+2 fraction) from hydrolyzed genomic DNA of dissected
livers from WT and lf:Yap fish as determined by LC-MS. p < 0.05.
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incorporated into the DNA than WT controls, with 3 times more deoxyinosine, twice as
much deoxyguanosine and 65% more deoxyadenosine (Figure 2.4.17 C). This Yap-dependent
increase was mitigated to baseline levels by exposure to MSO. The 15N flux data suggest
that Yap reprograms nitrogen metabolism by stimulating anabolic incorporation of glutamine
into nucleotides in a Glul-dependent manner. In order to evaluate the potential therapeutic
impact of Glul inhibition on adult liver hyperplasia, fish were exposed to MSO (twice a week
for 48 hr) over a 4-week period (Figure 2.4.18 A). This regimen efficiently inhibited Glul
activity (Figure 2.4.18 B, n = 3, p < 0.001) and significantly reduced hepatomegaly in lf:Yap
transgenics (Figure 2.4.18 C, n > 9, p < 0.05). MSO exposure had no effect on liver size
in WT fish and overall fish appearance, suggesting that Glul is conditionally required for
hepatic growth. MSO exposure did not cause cell death as determined by TUNEL staining
(Figure2.4.18 D). Collectively, these data show that Yap elevates Glul activity and produces
glutamine that is essential for the biosynthesis of nucleotides required for DNA synthesis
during rapid liver growth.
2.5 Discussion
In this study, we generated transgenic zebrafish that express activated Yap in hepatocytes
and demonstrate the rapid onset of embryonic hepatomegaly that persists into adulthood,
with a high susceptibility to DMBA-induced hepatocarcinogenesis. Using a combination
of transcriptomic and metabolomic analyses, we discover that Yap reprograms nitrogen
metabolism by inducing Glul and elevating the steady-state level of glutamine available
for biosynthetic growth. The transcriptional regulation of Glul by Yap is evolutionarily con-
served in human cell lines and cancers. Therapeutic studies with the Glul inhibitor MSO
revealed that elevated Glul activity contributes to Yap-driven hepatomegaly, making this
the first example documenting suppression of an oncogene-induced adult phenotype by ma-
nipulation of a metabolic enzyme using zebrafish as a model system. Collectively, our data
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Figure 2.4.18: Chemical Glul inhibition in adult zebrafish reduces Yap-induced
hepatomegaly. (A) Scheme describing the long-term intervention studies with MSO in
adult fish. (B) Glul activity in liver lysates extracted from WT and lf:Yap fish in the
presence or absence of MSO. (C) Effect of MSO intervention on Liver:Body weight ratios
in WT and lf:Yap adult fish. (D) Histological analysis of cell death (TUNEL) from WT
and lf:Yap transgenics derived from the long-term MSO intervention studies. The positive
control showing DAB-stained nuclei is derived from a murine liver section. p < 0.05.
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reveals that the Hippo pathway reprograms glutamine metabolism to provide cellular build-
ing blocks crucial for Yap-driven hepatic growth. Given that the Hippo pathway is frequently
deregulated in cancer, targeting the metabolic alterations caused by Yap activation may be
an attractive and rational therapeutic avenue.
Hippo pathway involvement in liver growth and tumorigenesis
Previous investigations in mice have demonstrated that Yap can alter liver cell fate, induce
hepatomegaly and promote tumorigenesis (Dong et al., 2007; Camargo et al., 2007; Zhou
et al., 2009; Benhamouche et al., 2010; Lee et al., 2010). Recent insights have shown that Yap
can reprogram mature hepatocytes into progenitor cells by activation of the Notch pathway
(Yimlamai et al., 2014). Yap promotes dedifferentiation of mature hepatocytes by influencing
Hnf4a and Foxa2 binding site choice and activating the expression of embryonic target genes
(Alder et al., 2014). Furthermore, Yap activation antagonizes the hepatic differentiation
programs directed by HNF4a and β-catenin, whereas loss of Yap function in murine HCC
causes tumor differentiation and regression (Fitamant et al., 2015). In the current study, we
expand this emerging area of research by discovering that the Hippo effector Yap reprograms
glutamine metabolism through induction of Glul, resulting in enhanced de novo nucleotide
biosynthesis to meet the anabolic demands of rapid cell proliferation. Interestingly, previous
ChIP-seq studies examining Yap and Tead target genes in MCF7 cells and embryonic stem
cells have also found that Yap was bound to the Glul promoter (Zhao et al., 2008; Lian
et al., 2010). Unlike other developmental signaling cascades, the Hippo pathway is not
activated by a single receptor, instead mounting evidence supports the notion that the Hippo
pathway is regulated by the integration of a plethora of environmental cues including cell-
cell contact (Zhao et al., 2007), cell polarity (Boggiano and Fehon, 2012), GPCR stimulation
(Yu et al., 2012), mechanical forces (Dupont et al., 2011; Aragona et al., 2013) and the
activation of other oncogenic pathways (Harvey et al., 2013). Consequently, it is possible
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that environmental cues in the early stages of liver disease, including the development of
fibrosis, activate Yap and provide a growth advantage for the initiation of cancer.
Crosstalk between the Hippo and Wnt pathways in the context of cancer
In the current study, we found that overexpression of Yap in zebrafish lead to the direct in-
duction of Glul. Previous work in mice has characterized Glul as a bone-fide Wnt target gene
(Benhamouche et al., 2006; Lachenmayer et al., 2012); however, in our study overexpression
of Yap directly induced Glul expression, while it did not modulate Wnt/β-catenin target gene
expression. The Hippo and Wnt pathways appear to have a very complex context-dependent
relationship. Pioneering studies found that Yap and Taz inhibit the Wnt pathway by binding
to Dvl or β-catenin directly (Imajo et al., 2012; Varelas et al., 2010a). Building on these stud-
ies, elegant work using transgenic mice has shown that intestinal-driven expression of Yap
inhibits the Wnt pathway and causes a rapid loss of intestinal crypts, whereas Yap depletion
activates Wnt and expands the stem cell niche (Barry et al., 2013). However, other studies
have reported that Yap activation enhances β-catenin activity. For example, in the context
of murine heart development, Yap binds β-catenin and they act in a coordinated fashion to
activate target genes to induce cardiomegaly (Heallen et al., 2011; Xin et al., 2011). Studies
in cultured cancer cells have found that Yap is essential for the transformation and survival
of β-catenin-driven intestinal tumors (Rosenbluh et al., 2012; Konsavage Jr. et al., 2012).
Recent insights from the Piccolo group have led to a model in which the authors propose
that Yap and Taz are sequestered in the β-catenin destruction complex and are released to
enter the nucleus upon Wnt stimulation (Aragona et al., 2013; Azzolin et al., 2012). Elegant
studies by Monga and colleagues have shown that Yap binds and activates β-catenin target
genes in the context of hepatoblastoma (HB), but not hepatocellular carcinoma (HCC) (Tao
et al., 2014). In summary, these studies highlight that the crosstalk between the Hippo and
Wnt pathways is nuanced, depending on cell type, the activation status of other signaling
cascades as well as microenvironmental factors that impinge upon each pathway.
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Our study provides clear evidence that the Hippo pathway can regulate Glul expression
in zebrafish and human hepatocytes independently of Wnt. Interestingly, we were unable
to observe a similar phenotype in mice because in our current experimental systems, Yap
rapidly reprograms murine hepatocyte cell fate (data not shown) (Yimlamai et al., 2014).
Previous studies have identified that Glul is overexpressed in human HB (Schmidt et al.,
2011), hepatocellular adenoma56 and early stage HCC (Nault et al., 2014; Christa et al.,
1994; Roskams and Kojiro, 2010). Groundbreaking studies by Colnot and colleagues used
conditional mouse mutants to demonstrate that the Wnt/β-catenin pathway plays a key
role in regulating Glul expression (Benhamouche et al., 2006; Lachenmayer et al., 2012;
Colnot et al., 2004). Subsequent genomic studies have revealed that components of the
Wnt pathway are frequently mutated in liver cancer (Guichard et al., 2012). In spite of
this, there are a subset of HCCs that overexpress Glul, which do not harbor mutations
in the Wnt pathway (Lachenmayer et al., 2012), suggesting that alternative pathways may
converge on the regulation of Glul expression. Additional factors that have been implicated
in Glul induction in other contexts include Met (Yuneva et al., 2012), Gata3 (Kung et al.,
2011), the Glucocorticoid receptor (Abcouwer et al., 1995, 1996; Chandrasekhar et al., 1999;
Labow et al., 2001) and Foxo van der Vos et al. (2012). Given the pivotal role that Glul
plays in nitrogen metabolism, it is likely there is redundancy with alternative signaling
pathways capable of regulating Glul expression. Our work together with previous studies
provide support for the hypothesis that Glul overexpression in liver tumor cells may provide
a competitive advantage by fulfilling the biosynthetic demands for rapid cell proliferation.
Metabolic reprogramming in cancer
One of the key features of malignancy is altered cellular metabolism. Tumor cells exploit
metabolic pathways to increase nutrient uptake and bioenergetic output. Aerobic glycolysis
(“Warburg effect”) and glutaminolysis are among the most well described metabolic changes
in cancer (Vander Heiden et al., 2009; Hensley et al., 2013). Interestingly, recent insights
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have shown that stem cells exploit metabolism in a similar manner to cancer cells by ele-
vating glycolytic flux and becoming more dependent on glutamine for lineage specification
(Shyh-Chang et al., 2013a,b; Oburoglu et al., 2014). An often-overlooked aspect of cancer
cell metabolism is the need to rewire carbon and nitrogen flux to generate the building
blocks required to fulfill the biosynthetic (anabolic) needs of rapid cell growth (Howell et al.,
2013). Recent studies examining the metabolic profiles of the NCI-60 cell line panel (Jain
et al., 2012), Kras-induced pancreatic cancer (Ying et al., 2012) and Myc-driven lymphomas
(Cunningham et al., 2014) have identified that a common theme in metabolic reprogram-
ming is the production of precursors that stimulate de novo nucleotide biosynthesis. In the
current study, we revealed that Yap reprograms glutamine metabolism and stimulates de
novo nucleotide biosynthesis. Although we focused our attention on the fate of glutamine,
we predict that Yap can alter the expression of other metabolic enzymes to remodel cel-
lular metabolism. It will be of interest in future studies to examine whether Yap-driven
metabolic reprogramming is coupled to cellular reprogramming to a progenitor-like cell fate.
Together, these data provide compelling evidence illustrating how oncogenic pathways co-opt
metabolism to promote tumor growth.
Parallels between how the mTOR and Hippo pathways integrate nutrient status
and anabolic cell growth
It is well established that functional crosstalk exists between the mTOR and Hippo pathways
during cell growth (Tumaneng et al., 2012a). The mTOR pathway plays a key role in
linking nutrient status with metabolic processes underlying anabolic cell growth (Dibble and
Manning, 2013). Intracellular nutrients like glucose and amino acids activate mTOR and
this alters the metabolic flux to generate the lipids, protein and nucleic acids required for
cell proliferation. For example, mTOR stimulates de novo lipid and protein synthesis via
activation of SREBP and inhibition of 4E-BP1 respectively (Duvel et al., 2010; Li et al., 2010;
Laplante and Sabatini, 2012). More recently, elegant studies have provided evidence that
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the mTOR pathway phosphorylates and thereby activates CAD, the rate-limiting enzyme in
de novo pyrimidine biosynthesis (Ben-Sahra et al., 2013; Robitaille et al., 2013). Similarly,
emerging work supports the notion that the Hippo pathway effector Yap is regulated by
nutrient cues in the cellular environment. The role that Yap plays in “sensing” nutrient status
was first revealed in studies identifying that serum-borne lipids such as lysophosphatidic
acid and sphingosine 1-phosphate regulate Yap (Yu et al., 2012; Miller et al., 2012). At
the mechanistic level, serum starvation activates Amot130, which binds Yap and facilitates
its degradation by recruiting the E3 ubiquitin ligase Aip4 (Miller et al., 2012; Adler et al.,
2013). In addition to serum starvation, recent work has shown that glucose deprivation
and bioenergetic stress inhibit Yap activation via AMPK (DeRan et al., 2014; Wang et al.,
2015; Mo et al., 2015; Enzo et al., 2015). Innovative studies by Sorrentino et al. have
demonstrated that the mevalonate pathway is required for Yap activation (Sorrentino et al.,
2014). In the context of liver growth, recent studies have shown that bile acids activate Yap
to promote carcinogenesis (Anakk et al., 2013). In light of these studies and the new insights
provided by our work, we hypothesize that Yap functions to “sense” the nutrient status of
the environment and initiate an appropriate growth response. Given the striking similarities
between the mTOR and Hippo pathways as networks that integrate metabolite availability
to anabolic cell growth, it would be interesting to further explore these links in the context
of cancer.
In summary, our study provides compelling evidence that metabolic reprogramming con-
tributes to the hyperplastic growth phenotype imbued by Yap. A greater understanding of
the metabolic perturbations specific to malignant cells may provide new pharmacological
approaches to combat cancer.
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Chapter 3
The Role of Yap in Glucose Metabolism
During Liver Development
3.1 Abstract
The metabolic state of stem and progenitor cells is an important regulator of self-renewal and
proliferation; however, how these metabolic processes contribute to development and organ
growth remains poorly understood. One particular question is how cells are able to turn
on metabolic pathways as they meet the demands of rapid cellular growth and halt these
processes as the organ reaches its final size. In order to understand these basic mechanisms,
developmental metabolism studies are needed. This is of particular interest since tumor cells
have been shown to display these same metabolic properties of rapidly proliferating cells but
fail to stop growth and instead exploit these processes for their proliferative advantage.
In organ development, the Hippo signaling pathway has emerged as a central regulator of
organ size by controlling cell proliferation and growth. How it is able to coordinate normal
development and the metabolic demands of its proliferative capacity, though, has not been
explored. Here, we utilize the zebrafish to investigate the role of Yap, the transcriptional co-
activator and downstream target of the Hippo pathway, in liver organogenesis and embryonic
metabolism. Using a viable yap knockout zebrafish model and heat shock inducible yap
modulating transgenic fish lines, we show that Yap plays a role in hepatic progenitor cell
populations that is critical for liver growth. Transcriptome analysis revealed that glucose
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transporters 1 and 2 (glut1/2 ) expression are decreased in yap knockout embryos. Further
metabolomic analysis revealed that Yap plays a critical role in nucleotide biosynthesis and
glucose metabolism in the developing embryo, and in vivo flux labeling showed Yap channels
glucose into purine and pyrimidine precursors. In order to determine whether glucose uptake
is critical for Yap-induced proliferation, we chemically inhibited glut1 glucose transport with
WZB117, and showed that glut1 is critical for Yap-induced hepatomegaly. We propose that
Yap regulates glycolytic flux into the biosynthesis of nucleotides required for anabolic growth
in the developing embryo.
3.2 Introduction
Development of a multicellular organism with specialized tissues from a single cell requires
complex signals and rapid decisions of proliferation and differentiation while maintaining
ample bioenergetics and macromolecular building blocks for rapid cell growth. Features of
rapidly dividing cells have been elucidated through cancer studies and have shown some
common metabolic features, mainly increased rates of glucose uptake, increased rates of
glucose metabolism by anaerobic glycolysis even with oxygen present (aerobic glycolysis), and
shunting of glycolytic intermediates into anabolic pathways for biomass production (Vander
Heiden et al., 2009; Mayers and Vander Heiden, 2015). Moreover, embryonic stem cells,
which proliferate rapidly, show these same characteristics (Shyh-Chang et al., 2013a). This
brings about the question as to how rapidly dividing cells in the embryo coordinate their
highly anabolic cellular needs with developmental pathways.
In the developing liver, many studies have examined the transcriptional and signaling
pathways required for hepatogenesis; however, little is known as to how these pathways reg-
ulate cellular metabolism (North and Goessling, 2011). In the zebrafish, liver organogenesis
begins with endoderm specification which is a result of multiple signaling pathways and tran-
scription factors that are integrated. Hepatic progenitors from this multipotent precursor
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population are specified and bud, eventually differentiating into hepatocytes and proliferating
to form the matured organ. The zebrafish liver develops from the anterior endodermal rod
by 24 hours post fertilization (hpf) identifiable by the progenitor markers prospero-related
homoebox 1 (prox1 ) and hematopoietically expressed homeobox (hhex ) (Field et al., 2003;
Shin et al., 2007; Chu and Sadler, 2009; North and Goessling, 2011). By 48 hpf, the liver
primordium is fully distinguishable as a bud to the left of the midline and hepatocytes begin
to differentiate, indicated by markers of liver fatty acid binding protein (lfabp) and group
specific component (gc) (Her et al., 2003b,a; Noël et al., 2010). Hepatic outgrowth then
commences between 60-72 hpf and continues until it achieves its appropriate size (Chu and
Sadler, 2009).
The Hippo signaling pathway has emerged as a major regulator of post-natal liver growth
and organ size determination. Yap, the downstream transcriptional co-activator of the Hippo
pathway, has been shown to regulate cell proliferation, growth, and survival and has been
implicated as a key regulator of stem and progenitor cells (Ramos and Camargo, 2012).
Originally discovered in Drosophila, the Hippo pathway has been found to be widely con-
served, with homologs of Yap in human, mouse, and zebrafish. The core components of
the pathway in mammalian systems include the kinases MST1/2 and Lats1/2, the adaptor
proteins Sav1 and Mob1, the transcriptional co-activators Yap and Taz, and the Tead family
transcription factors (Harvey et al., 2003; Udan et al., 2003; Pantalacci et al., 2003; Wu
et al., 2003; Tapon et al., 2002; Taguchi et al., 2010; Xu et al., 1995; Huang et al., 2005).
Activation of the signaling cascade results in Lats1/2 phosphorylating Yap and rendering it
to the cytoplasm, thereby inactivating its transcriptional activity (Zhao et al., 2007; Dong
et al., 2007). Yap hyperactivation causes uncontrolled cellular proliferation and oncogenic
transformation (Harvey et al., 2013). While many studies have elucidated functional roles
of Yap and its upstream regulators, how Yap coordinates the bioenergetic demands of form-
ing the cellular metabolic building blocks for proliferation has not been explored. Studies
of the role of Yap in development have been especially challenging as Yap knockout mice
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are embryonic lethal at E8.5, prior to the formation of many organs (Morin-Kensicki et al.,
2006). Utilizing, Yap+/- heterozygous mice, Yap has been found to have a critical effect on
post-natal liver proliferation and hepatic differentiation (Septer et al., 2012). Additionally,
a mouse model with liver specific conditional knockout of Yap revealed Yap is important for
hepatocyte survival and bile duct development (Zhang et al., 2010).
Here, to look at early liver development, we use yap knockout zebrafish that are able
to survive through embryonic development as well as newly developed heat shock inducible
transgenics to modulate Yap transcriptional activity. Utilizing these models, we probe the
role of Yap in hepatogenesis and discover that Yap plays an integral role in liver develop-
ment. Further studies to determine the underlying mechanisms of Yap driven proliferation
and organ growth control, through transcriptional and metabolomic studies, revealed Yap
regulates glucose metabolism and the de novo synthesis of purine and pyrimidines. We
show that loss of Yap downregulates glucose transporters, glut1 and glut2, and that glucose
transport is critical for Yap dependent growth and cellular proliferation. Together, our data
reveal that Yap is central in the modulation of glucose metabolism and glycolytic flux into
the anabolic nucleotide synthesis pathways in the developing embryo, and we hypothesize
this ability to direct glycolytic metabolites into DNA building blocks plays a crucial role in
the proliferation of progenitor populations critical for organogenesis.
3.3 Methods
Generation of transgenic fish lines and zebrafish husbandry
Zebrafish embryos, larvae, and adult fish were maintained according to Institutional Ani-
mal Care and Use Committee (IACUC-BIDMC) protocols. Lines used in this study include
wild-type (AB), Tg(-2.8fabp10a:eGFP)as3referred to as lf:GFP as previously described (Her
et al., 2003b,a), Tg(l-fabp:CFP-NTR)s891 referred to as lf:CFP-NTR as previously described
(Curado et al., 2007a), and Tg(lf:Yap) referred to as lf:Yap. For this study, we gener-
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ated Tg(hsp70:mCherry-2A-Flag-YapS87A ) referred to as hs:YapS87A and Tg(hs:dnYap-2A-
mCherry) referred to as hs:dnYap. We used the plasmids pME-YapS87A and pME-NLS-
YapDN generously provided by Dr. Brian Link (Medical College of Wisconsin, Milwaukee,
WI) to generate the heat shock inducibile transgenics. YapS87A was amplified from pME-
YapS87A using the forward (5’-AAA AGA ATT CAg act aca aag acg atg acg aca agG ATC
CGA ACC AGC ACA ACC-3’) and reverse (5’-AAA AAG AAT TCC TAT AGC CAG GTT
AGA AAG TTC TCC-3’) primers to add a Flag-tag (lower case) and EcoRI restriction di-
gest sites (underline). The resulting product was digested with EcoRI-HF (NEB) and cloned
into the Tol2 kit vector p3E-2A-pCS2MCS-pA previously digested with EcoRI-HF and calf
intestine phosphatase treated (Kwan et al., 2007). The resulting plasmid was recombined by
Gateway (Life Technologies) recombination with Tol2 kit plasmids pDestTol2pA, p5E-hsp70i
and pME-mCherry-nostop to place the heat shock cognate promoter (hsp70i) upstream of
the constitutively active YapS87A followed by a 2A self cleaving linker sequence and mCherry
reporter gene. To create the Tg(hs:dnYap-2A-mCherry), QuikChange lightning site-directed
mutagenesis (Agilent Technologies) was used to delete the stop codon from the plasmid
pME-NLS-YapDN with the oligos 5’-AGA AGG AGA GAC TGA GGA ACC CAG CTT
TCT TGT A-3’ and 5’-TAC AAG AAA GCT GGG TTC CTC AGT CTC TCC TTC T-3’.
The resulting plasmid pME-NLS-YapDN-nostop was recombined by Gateway cloning with
Tol2 kit plasmids pDestTol2pA, p5E-hsp70i and p3E-2A-mCherry-pA. To generate stable
transgenic lines, we co-injected our newly generated plasmids with Tol2 Transposase RNA
into one-cell AB embryos. Adult founders (F0) were identified by screening their progeny for
heat shock inducible mCherry expression. The F1 generation’s progeny were then screened
for Mendelian inheritance, inducible mCherry expression and brightness, and quantification
of mCherry Hippo target gene mRNA expression.
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Heat shock conditions
Embryos were heat shocked by transferring them into pre-warmed 38 °C E3 (fish) water and
incubating them at 38 °C for 30 min. Genotype was determined by the presence of mCherry
fluorescence at 3 hours post heat-shock. Sorted non-fluorescent (wild-type) siblings were
used as controls.
Fluorescence microscopy and quantification
Live fluorescence microscopy was performed on lf:GFP and lf:CFP-NTR embryos that were
put under anesthesia with 0.04 mg/ml Tricaine-S. Embryos were imaged using a Zeiss Dis-
covery V8/Axio Cam MRC with the Axiovision software suite (Carl Zeiss). Fluorescent
images obtained of embryonic livers were processed and quantified using the freeware FIJI
(Schindelin et al., 2012).
Histology
Paraformaldehyde-fixed embryos were paraffin-embedded, cut into serial sections and stained
with Hematoxylin and Eosin (H&E) using standard techniques.
Whole mount in situ hybridization
Zebrafish embryos were fixed in 4% paraformaldehyde (PFA) at the specified stages, and in
situ hybridization was performed according to established protocols
(http://zfin.org/ZFIN/Methods/ThisseProtocol.html). RNA probes for ifabp, trypsin, gc,
lfabp, prox1, hhex, and foxA3 were used. Embryos were imaged in glycerol with a Zeiss
Discovery V8/Axio Cam MRC with the Axiovision software suite (Carl Zeiss). Prox1 and
lfabp expression areas were quantified using FIJI.
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RNA-seq and GSEA and GO analysis
Embryos were collected from incrossed yap-/-zebrafish and sorted based on phenotype at
72 hpf. RNA was extracted with Trizol (Life Technologies) and purified using the Qiagen
Rneasy kit (Qiagen) according to the manufacturers instructions. RNA quality was checked
using an Agilent Bioanalyzer and sequenced using an Illumina platform. polyA sequence
data was annotated on a genomic reference (ZV9) to identify differentially affected genes.
Raw data files were first QC’d using FASTQC. Almost all reads from all the samples were
of good quality (phred quality score > 30). The reads were then aligned with STAR in
paired-end mode. After sorting and indexing, the aligned files were used with bedtools and
Ensembl zebrafish transcriptome to generate read counts for genes for all samples. These
read counts were used with DESeq for differential expression and orthology was determined.
Read counts were also normalized with limma and orthologous human gene names were used
with GSEA for gene set enrichment analysis. Gage and pathview was used for pathway
analysis and GO Term enrichment on normalized reads counts.
Quantitative PCR
RNA was isolated from pooled zebrafish embryos (n = 30) using Trizol (Life Technologies)
and purified with Direct-zol RNA MiniPrep (Zymo Research). Following Turbo DNAse
treatment (Life Technologies), cDNA synthesis was performed using the iScript cDNA syn-
thesis kit (BioRad). Quantitative PCR (qPCR) was performed with technical triplicates on
biological triplicates using a CFX96 Touch cycler (BioRad) with iTaq SYBR green supermix
(BioRad). Relative expression levels were determined using the ΔΔCt method and Ef1α was
used as the reference gene. Primer sets for ef1α, mCherry, ctgf a, amotl2b, glut1 and glut2
can be found in Table 3.3.1.
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Table 3.3.1: Sequences of qPCR primers.
Gene Forward Primer Reverse Primer
ef1α GCGTCATCAAGAGCGTTGAG TTGGAACGGTGTGATTGAGG
mCherry GAACGGCCACGAGTTCGAGA CTTGGAGCCGTACATGAACTGAGG
ctgfa CTACGGCTCCCCAAGTAACC TCCACTGCGGTACACCATTC
amotl2b TCCCAGCACAACAGACTTCC CCGTTTGTCCCTCTAGCTCC
glut1 AAGCCAAGAGCGTGCTAAAG CGGTACAGTGATGAGCGGAA
glut2 TTAACAGGCACGCTCGCTCT TTCATGCTCTGTGCCATTTCC
Chemical exposure
Embryos were exposed to either 10 μM or 20μM WZB117, a Glut1 inhibitor (Liu et al.,
2012), (Sigma-Aldrich) in DMSO as described.
Steady-state metabolomics
WT and yap-/-embryos were collected at 72 hpf and a methanol extraction was performed.
Polar metabolites were isolated and enriched using the methodology outlined by Yuan et al
(Yuan et al., 2012). Polar metabolites were quantified using selected reaction monitoring on
a 5500 QTRAP hybrid triple quadrupole mass spectrometer.
Flux analysis of 13C-glucose
WT and yap-/- embryos were incubated in E3 (fish) water with 1% U-13C-glucose for 24
hours and then harvested.
3.4 Results
Yap knockout zebrafish are able to survive through embryogenesis and display
defects in liver development
In mice, genetic deletion of Yap is embryonic lethal, making it impossible to study the role of
Yap in early liver development (Morin-Kensicki et al., 2006). In order to characterize the role
of Yap in early hepatic development, we utilized Yap knockout zebrafish (yap-/-) generated
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Figure 3.4.1: Yap knockout zebrafish display developmental defects. Lateral view
of live (A) WT, (B) yap-/-mutant zebrafish with the mild phenotype, and (C) yap-/-mutant
zebrafish with the severe phenotype at 72 hpf.
by TALENs. These yap-/- zebrafish contain a 4 bp deletion in exon 1 at amino acid 53
leading to frameshift mutations and a premature stop codon 47 amino acids downstream.
We found the yap knockout zebrafish were able to survive gastrulation, and they displayed
a distinct phenotype with a range of severity (mild and severe). Notably, knockout embryos
at 72 hours post fertilization (hpf) exhibit hypopigmented eyes, cardiac edema, shortened
body axis, defects in yolk resorption, and curled tails (Figure 3.4.1). When raised at lower,
permissive temperatures (22 ºC instead of 28.5 ºC), some of the severe phenotypes were
suppressed. We noted that the yap-/- embryos with the mild phenotype were able to survive
past 5 dpf, and monitoring of the embryonic survival rate showed a similar survival of yap
knockout embryos compared to their phenotypic wild type (WT) siblings (one-third yap+/+
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Figure 3.4.2: . Survival rates for embryonic yap-/- zebrafish and their wild type
siblings. n > 200 embryos.
and two-third yap+/-) up through 5 dpf. At 6 dpf, yap-/- survival began to decrease, reaching
approximately 50% survival by 8 dpf (Figure 3.4.2).
A subset of our yap-/- zebrafish not only were able to survive through embryogenesis
but they also were able to to survive to adulthood. Of adult zebrafish generated from inter-
crossing yap+/- heterozygotes, 12.1% were homozygous knockouts, 56.1% were heterozygous,
and 31.8% were wild type (n = 264). This ability to survive through embryogenesis into
adulthood provides an advantageous model for examining the mechanisms of Yap in organo-
genesis.
To determine whether Yap was having an effect on endoderm organ development, we
performed in situ analysis for the hepatocyte marker group specific component (gc), the
intestinal marker intestinal fatty acid binding protein (ifabp), and the pancreatic marker
trypsin at 72 hpf. Uniformly, endoderm development was stunted and decreased liver, intes-
tine and pancreas sizes were observed. As we have shown the liver to be greatly influenced
by hepatocyte-specific Yap overexpression and transcritpional activation, we were interested
in understanding the role of Yap loss in liver development. To quantify the effect of Yap loss
on liver size, we crossed yap+/- heterozygotes into the reporter transgenic line Tg(lfabp:CFP-
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Figure 3.4.3: Yap knockout embryos display stunted growth of endoderm organs.
In situ analysis of endoderm organ makers (A,B) gc (liver), (C,D) ifabp (intestine), and
(E,F) trypsin (pancreas) show a marked decrease of organ size in yap-/- embryos (B,D,F)
compared to their phenotypic wild type siblings (A,C,E) at 72 hpf. n ≥ 30.
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NTR), referred to as lf:CFP-NTR, which specifically drives expression of cyan fluorescent
protein in hepatocytes. At 72 hpf, yap-/-;lf:CFP-NTR embryos display a 1.7-fold reduction
in liver outgrowth compared to their WT siblings when measured by fluorescent microscopy
(Figure 3.4.4 A,B). This decrease in liver size persists to 120 hpf with a 1.3-fold decrease
(Figure 3.4.4 C,D). Histological examination revealed that yap-/-livers are comprised of fewer
hepatocytes with a decrease in overall cellularity (Figure 3.4.5 A-C). In addition, we observed
that the liver appeared more midline at 72 hpf in yap-/- embryos, and by 5 dpf, a more mid-
line lobe was retained. These results suggest that Yap plays a crucial role in the development
of normal endoderm organ size, and this can be especially observed in liver development.
To gain further insight into whether Yap is affecting liver progenitor formation in liver
development, we performed in situ hybridizations for endoderm, hepatoblast, and hepatocyte
markers. yap-/-embryos displayed decreased endoderm budding and gut looping at 48 hpf as
measured by foxA3 expression as well as decreased expression of prox1 and hhex in the liver
region (Figure 3.4.6). These data demonstrate that Yap plays a crucial role in endoderm
and hepatoblast development.
Yap signaling during hepatoblast specification and expansion is required for liver
development
In order to complement these studies and dissect the temporal role of Yap transcriptional
activation on liver development, we developed heat shock inducible transgenic lines that are
driven by the heat shock cognate 70-kd protein promoter, hsp70, and express either a Flag-
tagged constitutively activated, nuclear localized form of Yap (hsp70:mCherry-2A-YapS87A ,
“hs:YapS87A ”) or a nuclear localized, dominant negative Yap (hs:dnYap-2A-mCherry, “hs:dnYap”)
with the red fluorescent reporter protein mCherry separated by a self-cleavable viral 2A pep-
tide linker sequence (Figure 3.4.7).
The dnYap was created by deleting the transcriptional transactivation domain and adding
a nuclear localization signal at the N-terminus to localize dnYap to the nucleus as otherwise
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Figure 3.4.4: Embryonic yap-/-embryos display decreased liver size. Embryos result-
ing from an incross of yap+/-;lf:CFP-NTR zebrafish display reduced liver size at (A) 72 hpf
and (B) 120 hpf as demonstrated by fluorescence microscopy. Quantification of liver area as
measured by fluorescence at (C) 72 hpf and (D) 120 hpf. Data are represented as individual
points with the horizontal line representing the mean ± S.E.M.; n ≥ 30 for each condition;
significant by t test comparing yap-/- to WT siblings; ***p≤0.001, ****p<0.0001.
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BA
Figure 3.4.5: Histology of embryonic livers at 120 hpf. (A) Hematoxylin and eosin
(H&E) staining in transverse sections of 120 hpf WT and (B) yap-/-embryos demonstrate
decreased hepatocytes in knockout embryos. Insets show magnified liver area.
deletion of the C-terminal PDZ domain results in cytoplasmic retention. A similar ortholog
construct has been utilized in human cell culture which was capable of effectively suppressing
TEAD activation (Cao et al., 2008; Nishioka et al., 2009). In order to determine the induction
of the heat shock response, embryos were heat shocked for 30 min at 38 ºC at 24 hpf. Heat
shock inducible hemizygous embryos were observed to have detectable mCherry fluorescence
beginning at 2 hours post heat shock and were able to be sorted from their wild type siblings.
Quantification of mCherry, which is transcribed at equimolar amounts to the Yap induced
transcript, by quantitative PCR (qPCR) showed effective expression of mCherry from 3 hours
post heat shock to 10 hours post heat shock with mCherry expression returning to baseline
at 24 hours post heat shock (Figure 3.4.8 A). In order to determine the transcriptional
activation or suppression of hs:YapS87A or hs:dnYap, respectively, we quantified known Yap
target genes, ctgf and amotl2b from 3 hours post heat shock to 24 hours post heat shock
(Figure 3.4.8 B,C).
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Figure 3.4.6: Yap is required for early liver development. WT and yap-/- embryos were
analyzed for prox1 (A,B), hhex (C,D) and foxA3 (E,F) expression by in situ hybridization
at 48 hpf. prox1 and hhex expression in the liver region (arrows) was diminished in the
mutant yap-/- embryos. Intestinal endoderm (brackets) marked by foxA3 expression also
showed diminished gut looping in the mutants. All images are representative dorsal views,
anterior left. n ≥ 30.
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Figure 3.4.7: Schematic of heat shock inducible transgenic constructs. Construct
hs:YapS87A contains the heat shock promoter, hsp70, that drives the red fluorescent pro-
tein, mCherry, separated by a viral 2A linker that encodes a self-cleavable peptide, and the
zebrafish Yap gene with a S87A mutation that localizes it to the nucleus and remain tran-
scriptionally active. The hs:dnYap construct is similarly driven by the hsp70 promoter and
an ectopic nuclear localization signal (NLS) was added to the N-terminus of the dominant
negative Yap which is missing the C-terminus transactivation domain.
In the hs:YapS87A transgenic fish, the constitutively activated form of Yap increased
expression of both ctgf and amotl2b from 6 hours post heat shock to 10 hours post heat shock.
Conversely, the hs:dnYap transgenic zebrafish suppressed expression of ctgf and amotl2b at
6 hours post heat shock. However, this suppression was relieved and a concomitant increase
in ctgf and amotl2b at 8 hours post heat shock was observed. This could be a result
of other unknown mechanisms compensating for the repression of these traditional Hippo
target genes in the developing embryo. These data demonstrate that we have an effective,
rapid and transient system for activating and reducing Yap transcriptional signaling in the
zebrafish embryo.
We next utilized our heat shock inducible transgenic zebrafish to probe whether Yap
transcriptional signaling is essential for hepatoblast formation. Prox1 and hhex are among
the earliest markers of hepatoblast differentiation from endoderm in the zebrafish, and their
expression initiates at approximately 22 hours post fertilization (Shin et al., 2007, 2011). To
determine whether Yap transcriptional activation is required for hepatoblast specification,
we outcrossed hemizygous hs:YapS87A or hs:dnYap zebrafish and heat shocked the resulting
embryos at 18 hpf prior to expression of hhex or prox1. In situ analysis of these heat shocked
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Figure 3.4.8: Time course of the transcriptional response following heat shock
induction. (A) Relative mCherry levels to ef1α of hs:YapS87A and hs:dnYap from 3 hours
post heat shock to 24 hours post heat shock measured by qPCR. Fold change of (B) ctgf or
(C) amotl2b relative to 0 hours heat shock were measured from 3 hours post heat shock to
24 hours post heat shock by qPCR with ef1α as the reference gene. All experiments were
done in biological triplicate. Data are represented as the mean ± S.E.M.
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embryos at 36 hours post fertilization revealed a decrease in expression of prox1 and hhex in
hs:dnYap embryos whereas activation of Yap increased prox1 and hhex expression (Figure
3.4.9 A-F).
Quantification of the prox1 hepatoblast area confirmed this decrease in hepatoblast size
in dominant negative Yap embryos and increased hepatoblast size in activated Yap embryos.
(Figure 3.4.9 J). Gut looping visualized by foxA3 expression also showed defective leftward
bending in dominant negative embryos whereas the constitutively active form of Yap showed
no change (Figure 3.4.9 G-I). These data suggest that Yap transcriptional activation is
required for hepatoblast proliferation and expansion.
We next investigated whether this decrease in hepatocyte precursor cell population due
to decreased Yap activity could affect liver size. To test this, we outcrossed outcrossed
hemizygous heat shock liver reporter fish hs:YapS87A;lf:CFP-NTR or hs:dnYap;lf:CFP-NTR
zebrafish and heat shocked the resulting embryos at 18 hpf. However, in the hs:dnYap;lf:CFP-
NTR outcross, we noted that the Mendelian inheritance of the CFP reporter gene with the
dominant negative Yap was less than expected (~25%), whereas the inheritance of CFP and
the constitutively active Yap was as expected (~56%), making us suspect that the decreased
number of hepatoblasts was resulting in decreased hepatocyte formation. To test this, we
performed in situ analysis for expression of the hepatocyte markers lfabp in hemizygous
hs:YapS87A and hs:dnYap embryos heat shocked at 18 hpf and measured at 72 hpf. We
analyzed liver area by lfabp expression area, and hs:dnYap embryos showed a significant
decrease in liver area with the majority showing no expression of lfabp; however, hs:YapS87A
embryos showed no change in liver size (Figure 3.4.10 A-C). To confirm the loss of expression
in hs:dnYap embryos was due to lack of hepatocytes and not only a result of decreased lfabp
expression, we performed in situ analysis for the hepatocyte marker gc (Figure 3.4.10 D-F).
The hs:dnYap embryos again showed a significant decrease in liver size and 56% of embryos
had no appreciable expression of gc. This suggests that a reduction in hepatoblast size from
decreased Yap activity in early liver development results in a decrease in liver formation and
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Figure 3.4.9: Yap is essential for hepatoblast expansion. Embryos resulting from
outcrossing hemizygous hs:YapS87A or hs:dnYap were heat shocked at 18 hpf and collected
at 36 hpf. In situ hybridization for prox1 (A-C) and hhex (D-F) revealed greatly reduced
expression of the hepatic progenitor markers (arrows) in hs:dnYap hemizygous embryos in
comparison to their wild type siblings. In situ hybridization for the endoderm marker foxA3
(G-I) showed frequent decreased leftward gut looping [brackets] in the hs:dnYap embryos
whereas it appears unaffected in the hs:YapS87A embryos. (J) Measurement of the prox1 ex-
pression area confirmed a significant decrease in hepatoblast expression in hs:dnYap embryos
compared to wild type siblings and a increase in hepatoblast expression in hs:YapS87Aembryos
compared to wild type. Data are represented as the mean ± S.E.M. All images are repre-
sentative dorsal views, anterior left. n > 30.
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Figure 3.4.10: Yap transcriptional activity is required for liver formation. Hem-
izigous hs:YapS87A, hs:dnYap, and their wild type siblings were heat shocked at 18 hpf and
harvested at 72 hpf. Expression of hepatocyte marker lfabp (A-C) and gc (D-F) was ana-
lyzed by in situ hybridization and demonstrated decreased expression in hs:dnYap embryos
compared to wild type and hs:YapS87A. Numbers in lower left corner of (E) and (F) denote
percentage of hs:dnYap displaying either decreased liver size or no detectable liver. (G)
Liver size was measured by area of expression of lfabp by in situ analysis. All images are
representative lateral views. NS = not significant; ****p < 0.0001; n > 30.
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organ size size. In combination with our data from the Yap knockout fish, this supports a
role for Yap in the proliferation and expansion of endoderm progenitor cells and that loss of
progenitor proliferation causes a decrease in organ size.
Yap modulates glucose transporters in the developing embryo at the transcrip-
tional level
To gain further insight into the downstream pathways responsible for Yap-driven organ
growth, we performed transcriptomic analysis of yap-/- embryos in comparison of their phe-
notypic wild-type siblings at 72 hpf as the and found yap knockout embryos had a number
of differentially regulated genes (Figure 3.4.11 A). Gene set enrichment analysis (GSEA)
confirmed that the known Yap target gene signature was differentially regulated in yap-/-
embryos (Figure 3.4.11 B,C). Surprisingly, some of the traditional Yap target genes, such as
ctgf and amotl2, were upregulated in yap-/- embryos. This suggests that other pathways or
transcriptional activators, such as the Yap paralog Taz, could be compensating for loss of
Yap activity for some known target genes, which is consistent with our finding of a compen-
satory increase in ctgf and amotl2b that we observed following dnYap-induced suppression
of these genes.
We next performed gene ontology (GO) analysis to probe which biological processes were
most affected by yap knockout in the developing embryo. Interestingly, there was a striking
representation of metabolic processes, specifically with regards to aerobic respiration (Figure
3.4.12).
Given the possibility that other compensatory mechanisms were affecting the yap-/- em-
bryonic transcriptional profile, we decided to compare the downregulated transcripts of yap-/-
embryos with the downregulated transcripts of yap-/-taz-/- embryos at 72 hpf (Dr. Brian Link
and Dr. Yariv Houvras, data not shown) and our previous profile of upregulated transcripts
in constitutively active Yap livers. Of these gene sets, there were 191 genes that overlapped
(Figure 3.4.13). Of note, the glucose transporter 1(glut1, slc2a1a), was amongst the most
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Figure 3.4.11: Transcriptional changes in yap-/- embryos at 72 hpf. (A) Heat map
of RNA-sequencing identified differential gene expression between yap-/- embryos and their
phenotypic wild type siblings that were generated from incrossing heterozygote Yap+/- ze-
brafish. There were 3050 genes with decreased expression and 3090 genes with increased
expression in Yap knockout embryos (p<0.05). Blue signifies lower expression and red sig-
nifies higher expression. (B) GSEA graph of the known Yap conserved signature based on
yap-/- expression vs wild type expression. Normalized enrichment score (NES) and p-value
are displayed. (C) Heat map of Yap conserved signature genes based on GSEA plot.
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Figure 3.4.12: Gene ontology analysis of yap knockout embryos. Selected results of
Gene Ontology biological processes downregulated in yap-/- embryos. The number of genes
represented is indicated and the x-axis is the log (p-value).
differentially downregulated in yap-/- and yap-/-taz-/-embryos and was also upreguated as a
consequence of Yap overexpression and activation in adult zebrafish liver (Figure 3.4.14 A).
Further, the glucose transporter 2 (glut2, slc2a2 ) was significantly downregulated in both
yap-/- and yap-/-taz-/-embryos (Figure 3.4.14 A). This was of particular interest based on the
GO analysis that suggested Yap plays a transcriptional role in the regulation of metabolic
processes.
We performed qPCR to validate reduced expression of glut1 and glut2 in yap-/- embryos
at 72 hpf and found that glut2 was significantly decreased whereas glut1 expression showed
slight decreased expression (Figure 3.4.14 B). The dependence of Yap transcriptional activity
on glucose transporter expression further was confirmed by qPCR analysis of heat shocked
hs:YapS87A and hs:dnYap embryos at 6 hours post heat shock. We found glut2 expression was
significantly enriched and glut1 showed trends of increased expression with activated Yap
expression. Glut2 was conversely downregulated with expression of the dominant negative
Yap (Figure 3.4.14 C).
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Figure 3.4.13: Venn diagram comparing differentially regulated genes. Genes signif-
icantly downregulated in yap-/- embryos (2393, blue) were compared to genes downregulated
in yap-/-taz-/- double knockout embryos (3984, green) and genes upregulated in lf:YapS87A
livers (1281, red). The Venn diagram shows the overlap between these groups. Number of
genes shared are indicated.
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Figure 3.4.14: Expression of glut1 and glut2 is decreased with loss of Yap tran-
scriptional activity and increased with Yap activation. (A) Heat map analysis of
RNA-seq data demonstrates decreased expression of glut1 and glut2 in yap-/- embryos with
an even greater decrease in yap-/-taz-/- embryos at 72 hpf. (B) Relative fold change of glut1
and glut2 in yap-/- embryos at 72 hpf normalized to WT siblings. (B) Relative fold change of
glut1 and glut2 in hs:YapS87A and hs:dnYap embryos compared to their WT sibling controls.
Embryos were heat shocked at 26 hpf and collected at 32 hpf. Data are represented as the
mean ± S.E.M. All experiments were done in biological triplicate. *p < 0.05.
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Yap modulates the metabolism of glucose in embryos and nucleotide biosynthesis
Since our transcriptomic analysis identified metabolism as being the most significant cellular
process being modulated by loss of Yap, we undertook unbiased polar metabolomic profiling
on yap-/- embryos and their WT siblings at 72 hpf using liquid choromatography-tandem
mass spectrometry (LC-MS) to identify cellular metabolic processes being modulated by
loss of Yap. Metabolite clustergram analysis revealed that yap-/- embryos had significantly
distinct metabolic profiles compared to WT in the steady-state (Figure 3.4.15 A). Most
notably, there was a significant decrease of metabolites associated with purine metabolism
in yap-/- embryos (Figure 3.4.15 B). Examination of nucleotide relative abundances in the
steady state showed a dramatic reduction in purine nucleotides in the Yap deficient embryos
compared to WT siblings, consistent with defects in purine metabolism (Figure 3.4.16).
Consistent with a decrease in glut1 and glut2 expression in yap-/- embryos, Yap deficiency
also led to significantly lower levels of most glycolytic intermediates, including glucose-6-
phosphate (G6P), fructose-6-phosphate (F6P), dihydroxyacetone phosphate (DHAP), and
glyceraldehyde-3-phosphate (G3P) with slight decreases in the other metabolites except for
fructose-1,6-bisphosphate (FBP) which showed an increase (Figure 3.4.17 A). Additionally,
yap-/- embryos had decreased lactate, consistent with a decrease in lactate dehydrogenase a
(ldha) expression found by transcriptome analysis (data not shown). Despite having signifi-
cant changes to glycolysis, we observed that steady-state levels of TCA cycle intermediates
were only slightly decreased and for the large part not significantly altered (Figure 3.4.17
B).
We therefore turned our attention to the anabolic pentose phosphate pathway (PPP) as
it diverts glucose derivatives from glycolysis into building the ribose ring of nucleotides.
In yap-/- embryos, we found metabolites of the nonoxidative branch of the PPP to be
significantly decreased, namely sedoheptulose-7-bisphosphosphate (S7P) and erythrose-4-
phosphate (E4P), whereas the oxidative arm of the PPP did not show significant changes.
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Figure 3.4.15: Steady state metabolomics reveals Yap modulates the metabolic
profile of embryos. (A) Clustergram analysis of polar metabolites in yap-/- and WT
embryos at 72 hpf as determined by LC-MS/MS selected reaction monitoring (SRM) analysis,
n = 4, p < 0.05. (B) Metabolite Set Enrichment Analysis (MSEA) of overrepresented
metabolites as determined by SRM analysis. The color code indicates the calculated p
value.
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Figure 3.4.16: Yap-/- embryos display dramatic reduction in purine nucleotides.
Relative abundances of deoxyribonucleotides and ribonucleotides as analyzed by LC/MS-
selected reaction monitoring (SRM) in WT and yap-/-embryos at 72 hpf. n = 4 with each
sample containing 30 embryos, *p ≤ 0.05,***p ≤ 0.001, ****p < 0.0001.
(Figure 3.4.18). This is in agreement with our found decrease in purines as the PPP is
responsible for generating ribose-5-phosphate for de novo purine nucleotide synthesis.
To elucidate the the metabolic fate of glucose and the relative pathway activities, we
developed a new protocol for whole organism in vivo 13C labeling and flux analysis in the
zebrafish. We incubated embryos in a 1% solution of U-13C-glucose in E3 (fish) water for 24
hours and then measured incorporation of glucose derived 13C into metabolites by LC-MS.
This flux analysis revealed decreased glucose incorporation into the nucleotide precursors
deoxyribose-phosphate, carbamoyl-L-aspartate, guanosine, cytosine, and dTDP in the yap-/-
embryos (Figure 3.4.19). This supports our steady state metabolic findings of decreased
purine metabolites in yap-/- embryos and suggests decreased de novo purine biosynthesis as
well as decreased pyrimidine biosynthesis. Further, a concomitant decrease in glycolytic flux
was observed (Figure 3.4.20) whereas the TCA cycle showed little change (Figure 3.4.21),
consistent with our steady state metabolomics data. Together, these data support an es-
sential role for Yap in nucleotide biosynthesis by reprogramming glucose metabolism into
directing its carbon backbone into purine and pyrimidine synthesis.
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Figure 3.4.17: Yap knockout leads to decreased steady state glycolytic interme-
diates with little change in TCA cycle intermediates in embryos. Relative abun-
dance of (A) glycoytic metabolites and (B) TCA cycle metabolites measured by LC-MS-
selected reaction monitoring (SRM) analysis in WT and yap-/-embryos at 72 hpf, relative
to WT. Data represented as mean ± S.E.M., n = 4, *p < 0.05, **p < 0.01. G6P, gluscose-
6-phosphate; F6P, fructose-6-phosphate; FBP, fructose-1,6-phosphate; DHAP, dihydroxy-
acetone phosphate; G3P, glyceraldehyde-3-phosphate; B(1,3)PG, 1,3-bisphosphoglycerate;
3PG, 3-phosphoglycerate; 2PG, 2-phosphoglycerate; PEP, phopshoenolpyruvate.
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Figure 3.4.18: Yap-/- embryos display decreased nonoxidative Pentose Phosphate
Pathway metabolites. Fold change of steady-state metabolites of the oxidative and
nonoxidative branch of the Pentose Phosphate Pathway (PPP) measured by LC-MS/MS-
SRM analysis in WT and yap-/- embryos at 72 hpf, relative to WT (n = 4). Data
represented as mean ± S.E.M. ***p ≤ 0.001, ****p , 0.0001. G6P, glucose-6-phosphate;
GδLSP, 6-phosphoglucono-δ-lactone; 6PG, 6-phosphogluconate; R5P, ribose-5-phosphate;
S7P, sedoheptulose-7-bisphosphosphate; E4P, erythrose-4-phosphate.
Glut1 inhibition is able to suppress Yap-induced hepatomegaly
In order to examine whether glucose uptake by Glut1 plays a role in the ability of Yap to pro-
mote proliferation and hepatomegaly, we treated our previously described lf:YapS87A;lf:GFP
zebrafish embryos with the Glut1-specific inhibitor, WZB117 (Liu et al., 2012), during the
liver expansion phase of development (72-120 hpf) and measured liver area by fluorescence
microscopy (Figure 3.4.22). Strikingly, we found Glut1 inhibition reduced Yap-induced hep-
atomegaly, in a dose dependent manner, to wild type liver sizes without affecting wild type
normal liver growth. These data suggest that Yap-dependent growth requires glucose uptake
through Glut glucose transporters and that Yap promotes the usage of glucose into de novo
nucleotide biosynthesis.
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Figure 3.4.19: Yap deficiency leads to decreased metabolic flux into purine and
pyrimidine synthesis. Metabolic flux analysis of yap-/- and WT embryos incubated in a so-
lution of U-13C-glucose showed decreased glucose conversion into (A) deoxyribose-phosphate,
(B) guanosine, (C) carbamoyl-L-aspartate, (D) cytosine, and (E) dTDP. y-axis represented
as a fraction of 13C isotopomer fraction. n = 3. **p ≤ 0.01.
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Figure 3.4.20: Yap-/- embryos display decreased flux through glycolysis. Metabolic
flux analysis of U-13C-glucose shows decreased 13C isotopomer abundance in (A) glucose-
1-phosphate (G1P), (B) fructose-1,6-bisphosphate (FBP), (C) glyceraldehyde-3-phosphate
(G3P), (D) dihydroxyacetone phosphate (DHAP), and (E) 3-phosphoglycerate (3PG). y-
axis represented as a fraction of 13C isotopomer fraction. n = 3.
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Figure 3.4.21: TCA cycle flux is not influenced by loss of Yap. TCA cycle 13C-
isotopomers (A,B) citrate and (C,D) a-ketogluterate were not changed in yap-/-embryos
compared to wild type. y-axis represented as a fraction of 13C isotopomer fraction. n = 3.
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Figure 3.4.22: Inhibition of Glut1 decreases Yap-induced hepatomegaly. (A-F) Fluorescence
microscopy of lf:GFP and lf:Yap;lf:GFP zebrafish embryos treated from 72-120 hpf with
either (A,B) DMSO, (C,D) 10 μM of Glut1 inhibitor WZB117, or (E,F) 20 μM WZB117.
(G) Quantitative analysis of the effect of WZB117 treatment on liver size as determined by
fluorescence microscopy. Data are represented as the mean ± S.E.M. ****p < 0.0001. n >
100.
90
Chapter 3. The Role of Yap in Glucose Metabolism During Liver Development
3.5 Discussion
In this study, we provide evidence that the highly conserved transcriptional co-activator Yap
is required for normal growth of hepatic progenitors and liver organ size. Moreover, we
find that Yap regulates glucose uptake and promotes usage of the glycolytic carbon back-
bone into nucleotide biosynthesis. In yap knockout zebrafish, which are able to survive past
organogenesis and into adulthood, we find that they have reduced endoderm organ size, and
specifically greatly reduced liver size as well as defects in hepatoblast growth. We modulated
Yap activation during hepatoblast specification using newly developed heat shock transgenic
zebrafish, and found that Yap is critical for hepatoblast progenitor bud growth and devel-
opment into the mature embryonic liver. Deeper investigation into the mechanisms behind
the ability of Yap to promote proliferation and growth by transcriptomic and metabolomic
analyses revealed glucose transport, by control of expression of glut1/2, and glucose utiliza-
tion to synthesize nucleotides to be greatly decreased in the absence of Yap. Tracer label
studies confirmed that Yap plays a role in glucose metabolism and is required for the an-
abolic usage of glucose into purine and pyrimidine precursors. Targeted chemical inhibition
of glut1 reduced Yap-induced hepatomegaly in embryos to wild type liver sizes. Together,
our data identifies a novel role of Yap in glucose uptake and nucleotide biosynthesis in the
developing embryo. As glucose transport and its metabolism are frequently deregulated in
cancer, this provides new mechanistic insight into potential contributors of this cancerous
metabolic phenotype, and as such, reveals additional therapeutic targets.
The Zebrafish as a Model of the Hippo Pathway in Early Development and Liver
Development
The Hippo pathway and specifically Yap, the transcriptional co-activator and effector of the
pathway, are tremendously conserved throughout the animal kingdom (Hilman and Gat,
2011). Previous investigations in mice have found deletion of Yap to be embryonic lethal in
the first half of gestation, resulting from defects in early yolk sac vascular development and
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failure of chorioallantoic fusion (Morin-Kensicki et al., 2006). Whereas the Yap-/- mouse is
lethal, likely from its defect in the placental system, the yap-/- zebrafish is able to survive
through embryogenesis and into adulthood. This is likely a result of the zebrafish lacking
both yolk sac blood islands and the allantois (Zon and Bahary, 1998), giving it a distinct ad-
vantage of survival as it does not require these processes in development and instead develops
ex vivo. Mice with placental defects, in contrast, tend to always be early embryonic lethal
(Drake, 2003). Despite this early embryonic lethality in mice, some similar observations can
be made between the yap-/- zebrafish embryos and the Yap-/- mouse embryos prior to their
death (Morin-Kensicki et al., 2006). We identified yap-/- zebrafish to display a range of mor-
phological variability, and Yap-/- mouse embryos also had a range of phenotype from almost
normal to severely abnormal. Further, we observed defects in embryo body lengthening and
mediolateral defects in endoderm progenitor development which was recapitulated in mice
lacking Yap as they had a failure to elongate the body axis and had defects in mediolateral
patterning (Morin-Kensicki et al., 2006). Intriguingly, in a recent study examining the hir
medaka fish mutant, a morphologically flattened body and tissue misalignment was found
to be due to a mutation in Yap, which caused a decrease in tissue tension (Porazinski et al.,
2015). This suggests that Yap plays not only a role in proliferation and progenitor cell
formation but also a central role in organ and body shape.
Our phenotypic findings of smaller endodermal organs and decreased hepatoblast progen-
itors in yap-/- embryos support a role for Yap in proliferation, growth, and organ formation.
These properties have similarly been seen in other studies using morpholino knockdown of
yap in zebrafish, as a decrease in yap caused defects in brain development, cardiogenesis,
hematopoiesis, renal development, and retina development (Jiang et al., 2009; Skouloudaki
et al., 2009; Hu et al., 2013; Fukui et al., 2014; Loh et al., 2014; Porazinski et al., 2015).
Consistent with our finding of transcriptional activation of Yap to be essential for progenitor
cell population size, Yap has been implicated in the survival of neuroprogenitor cells in the
chick (Cao et al., 2008) and maintenance of neuromast progenitor cells in the lateral line
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(Loh et al., 2014). Further, Yap was found to regulate Prox1 expression in neuromasts, which
supports our finding of decreased prox1 positive hepatoblasts in yap-/- embryos as well as
embryos expressing the dominant negative Yap. Interestingly, in lateral line development,
prox1 mRNA expression could rescue the number of differentiated mechanoreceptors in yap
knockdown embryos, suggesting prox1 repletion in hepatoblasts deficient for yap could rescue
liver formation (Loh et al., 2014).
Our findings that Yap expression is important for hepatoblast progenitor populations
are consistent with Hippo activity in the developing endoderm as seen in Hippo reporter
transgenic fish, which contains four consensus Tead binding sites upstream of a troponin
minimal promoter that drives fluorescent protein expression (Miesfeld and Link, 2014). In
these embryos, high fluorescence is seen in undifferentiated endoderm as well as cardiac
progenitor cells and muscle of the trunk (Miesfeld and Link, 2014). Furthermore, yap mor-
phants showed endodermal widening, and targeted yap depletion in endoderm-fated cells
demonstrated defects in endoderm formation (Fukui et al., 2014). Yap morphants also have
shown yap is activated in the endoderm by sphingosine 1-phosphate (S1P) and reduced yap
activity results in defects in the endodermal sheet and cardia bifida (Fukui et al., 2014).
These studies in combination with our observation of defects in hepatic bud formation and
decreased formation to the left of midline suggest that the Hippo pathway may further facil-
itate the crosstalk between mesoderm and endoderm development. A number of extremely
well defined mesodermal signaling pathways, namely Wnt, FGF and Bmp, have elegantly
been shown to play a fundamental role in hepatoblast specification (North and Goessling,
2011). Our findings are reminiscent of defects in Bmp signaling in the zebrafish in which
disruption of Bmp during hepatic specification results in decreased hepatoblast formation
and laterality defects (Shin et al., 2007). However, it is important to note that our data does
not provide information regarding whether Hippo signaling in the mesoderm or endoderm
is most critical for liver development and additional studies are needed. Further, our ob-
servation of decreased hepatoblast markers prox1 and hhex in hepatoblast budding in yap-/-
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embryos and hs:dnYap embryos could be a result of deficiencies in specification, proliferation
or increased cellular death. Surprisingly, while heat shock induction of the constitutively
active form of Yap increased progenitor cell population size, we did not observe a concomi-
tant increase in liver size. This could be a result of the short temporal response of the heat
shock induction. Further, previous gain-of-function zebrafish experiments in which mRNA
encoding for yap was injected into embryos similarly did not show increases in organ size or
overgrowths (Gee et al., 2011; Loh et al., 2014).
Role of Glucose Transporters in Cancer and Development
We find glucose transporters 1 and 2 (glut1/2 ) are downregulated in yap-/- and yap-/-taz-/-embryos
and are downregulated with heat shock driven expression of a dominant negative Yap and
conversely upregulated by heat shock activation of a transcriptionally active Yap within 6
hours of heat shock. This is of particular interest as glucose availability is a rate limiting
step to glycolysis and glucose transporter expression is highly transcriptionally regulated.
Additionally, a marked increase in glucose uptake with increased aerobic glycolysis is a char-
acteristic feature of cancer cells, originally described by Otto Warburg almost a century ago
(Warburg et al., 1926; Koppenol et al., 2011). This property of increased glucose uptake
in cancer has since been harnessed for cancer detection through positron emission tomog-
raphy (PET) imaging of a radioactive glucose, fluorodeoxyglucose (18F-FDG), that detects
high-glucose uptake, and as such, preferentially labels high-glucose consuming tumors.
To date, fourteen family members of the facilitative glucose transporters have been de-
scribed in mammals (Medina and Owen, 2002). Glut1 is is a rate-limiting facilitative trans-
porter for glucose uptake and is normally ubiquitously expressed at low levels. However,
elevated Glut1 expression has been reported in many different cancers, including hepatic,
pancreatic, breast, esophageal, brain, renal, lung, cutaneous, colorectal, endometrial, ovar-
ian, and cervical carcinoma (Macheda et al., 2005). Further, it has been correlated with
poorer prognosis and more aggressive tumor behavior, especially in hepatocellular carcinoma
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and cholangiocarcinoma (Amann et al., 2009). Glut2, on the other hand, is a low-affinity
glucose transporter that is primarily expressed in the liver, pancreas, and retina in adult
tissues. Glut2 is also overexpressed in some cancers, including gastric, breast, colon and
liver carcinoma, and has been found to be highly specific for high-grade precursor lesions in
cholangiocarcinoma (Medina and Owen, 2002; Kubo et al., 2014). While Glut2 is the normal
glucose transporter in pancreas and Glut2 is associated with high-grade precursor lesions,
Glut1 has been the main glucose transporter overexpressed in the progressed tumors (Med-
ina and Owen, 2002). This suggests that glucose transporter expression can be differentially
expressed based on the specific cellular background and cancer.
Interestingly, glucose transporters have been found to be regulated by oncogenic path-
ways. Early experiments identified that transformation of cells with oncogenes such as Src,
Ras, or FSV caused early induction of Glut1 expression (Flier et al., 1987; Birnbaum et al.,
1987). Oncogenic pathways that have further been implicated in glucose transporter activity
are PI3K/Akt signaling (Kohn et al., 1996), Myc (Osthus et al., 2000; Louro et al., 2002;
Dang et al., 2008), and p53 (Kawauchi et al., 2008; Zhang et al., 2013). As Yap has been
shown to be a potent oncogene, this is in line with our findings of glut1 and glut2 expression
being decreased in yap knockout embryos. While we do not know whether this is a direct
effect on transcriptional regulation, intriguingly there is a putative Tead binding consensous
motif in the glut1 enhancer region. Supporting our finding that Yap causes differential ex-
pression of glucose transporters, Yap has been shown to upregulate expression of the glucose
transporter 3 (Glut3) in human cell lines (Wang et al., 2015). While we did not observe glut3
specifically to be deregulated by yap loss in zebrafish embryos, this could be a result of the
differential context of glucose transporters in the developing zebrafish embryo and human
cell lines.
Glucose transport is of special interest in the context of development as glucose trans-
porter expression is altered as cells differentiate and glucose metabolism seems to play a
critical role in stem cell identity. Indeed, Glut1 and Glut3 are upregulated in blastocyts
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requiring highl levels of glycolysis (Pantaleon and Kaye, 1998). Furthermore, muscle progen-
itor cells, known as satellite cells, express high levels of Glut1 and Glut3 during myogenesis
(Guillet-Deniau et al., 1994). As the Hippo signaling pathway has shown marked activity in
the muscle and Yap is required for satellite cell activation (Judson et al., 2012), this provides
another potential connection between Yap transcriptional activity and glucose transporter
expression.
Integration of metabolic signaling in the Hippo Pathway
Our work demonstrates that Yap plays a crucial role in the metabolism of glucose and
synthesis of nucleotides as we observed decreased glycolysis and biosynthesis of purine and
pyrimidine precursors in yap knockout embryos both in steady state metabolite measure-
ments and tracer label flux studies. This influence of Yap on glycolytic flux into nucleotide
biosynthesis is a common trademark of cancer cells that direct glucose metabolism into an-
abolic pathways (Vander Heiden et al., 2009). Furthermore, loss of oncogenic Kras resulting
in decreased glycolytic flux into the anabolic PPP pathway (Ying et al., 2012) is reminiscent
of our findings in yap knockout embryos. Very recently, Yap has been shown to be regu-
lated by the presence of glucose itself. Energy stress on cells in culture either by glucose
deprivation or treatment with 2-deoxyglucose, which is unable to undergo further glycolysis,
caused Yap activity to be decreased through activation of AMPK which then phosphory-
lates and activates Lats1/2 for phosphorylation and inhibition of Yap (Mo et al., 2015; Wang
et al., 2015; Enzo et al., 2015). When cells were released from energy stress, Yap was found
to translocate to the nucleus and interact with Tead to promote transcription of its target
genes (Wang et al., 2015). Furthermore, Yap phosphorylation, and hence its cytoplasmic
retention, was greater in the liver of fasted mice whereas in the livers of fed mice, Yap was
less phosphorylated and was nuclear localized, promoting transcription (Wang et al., 2015).
Consistent with a role of metabolic cues as regulators of the Hippo pathway, the mevalonate
pathway, which is involved in the biosynthesis of cholesterol, was found to modulate Yap
96
Chapter 3. The Role of Yap in Glucose Metabolism During Liver Development
activity. In combination with our findings that Yap alters glucose uptake and glycolytic
flux for anabolic nucleotide biosynthesis, these studies provide the intriguing possibility that
the availability of nutrients and the metabolic reprogramming of cells for anabolic growth is
integrated by Yap. Finally, our discovery that chemical inhibition of Glut1 in vivo causes
Yap-driven proliferation to be reduced offers the intriguing possibility that therapeutics tar-
geted towards glucose uptake may be beneficial for cancer patients with high Yap activity
tumors.
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Conclusions and Future Directions
The Hippo signaling pathway is a powerful regulator of proliferation, growth, and organ
size. It requires, like all cellular growth signals, the necessary biosynthesis of the required
macromolecular building blocks to support high levels of cellular replication and division.
While many studies have investigated the upstream regulators of Hippo signaling, how the
Hippo pathway coordinates rapid cellular proliferation with the demands of anabolic synthe-
sis is unknown. Here we study the role of Yap, the evolutionarily conserved transcriptional
co-activator and downstream effector of the Hippo pathway, in its role in reprogramming
cellular metabolism.
In our first study, we established that the zebrafish is able to faithfully repeat the findings
of Yap-induced hepatomegaly with a transgenic model that specifically expresses a consti-
tutively active Yap in hepatocytes. We found Yap induces hepatocyte proliferation and
hepatomegaly, both during embryogenesis and in the adult, and that these pre-neoplastic
livers are more sensitive to carcinogen-induced cancers. Inquiry into how Yap is able to sup-
port this hypercellular proliferation revealed through transcriptomic and metabolomic anal-
yses that Yap directly upregulates glutamine synthetase (Glul) expression and reprograms
nitrogen metabolism for de novo nucleotide biosynthesis. Interestingly, we found that chem-
ical inhibition and genetic knockdown of Glul reduced Yap-driven hepatomegaly, suggesting
that Yap-regulated proliferation is partially dependent on the synthesis of glutamine. As
glutamine is a source of nitrogen for nucleotide biosynthesis, we wanted to conduct tracer la-
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beling studies to determine the fate of nutritional nitrogen in Yap-driven hepatocyte growth.
To accomplish this, we developed a novel protocol with nitrogen tracer labeling for in vivo
flux analysis in the zebrafish. Excitingly, we found that Yap reprograms nutritional nitrogen
flux into nucleotides and that this flux is dependent on glutamine synthetase activity. To-
gether, this data showed that Yap is able to reprogram nitrogen metabolism to provide the
necessary nucleotide building blocks for DNA required in cellular proliferation and growth.
We next harnessed the power of the zebrafish as a model for development and investi-
gated the role of Yap in liver progenitor formation. Utilizing a yap knockout zebrafish that
is viable through adulthood and heat shock inducible transgenic lines that modulate Yap
transcriptional activity, we found Yap is required for normal growth of endoderm organs as
well as hepatic progenitor cell populations. As the developing embryo has many metabolic
demands for cellular proliferation, we wondered whether Yap could be modulating cellular
metabolism in the developing embryo for the anabolic synthesis of necessary macromolecules.
Transcriptomic, metabolomic, and flux analyses revealed that Yap modulates glucose uptake
through expression of glucose transporters glut1/2 and diverts the carbon glucose backbone
into purine and pyrimidine precursors necessary for nucleotide biosynthesis. Inhibition of
glucose transporter glut1 decreased Yap-induced hepatomegaly in embryos to wild type liver
sizes. Altogether, these results reveal that Yap is able to reprogram glucose metabolism by
regulating glucose uptake and shunting glucose metabolites into nucleotide biosynthesis in
the developing embryo.
In total, these complementary gain-of-function and loss-of function studies provide the
first evidence that Yap directly modulates cellular metabolism for anabolic growth. We have
developed new in vivo methods for assessing metabolic fluxes in the zebrafish and using
these methods, we have demonstrated that Yap reprograms the cellular metabolism of both
glutamine, a nitrogen source, and glucose, a carbon source, into nucleotide biosynthesis to
support hyperproliferation and growth.
Our findings open many new avenues of research with regards to the role of Yap in
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cellular metabolism as well as how Yap influences these properties in the context of cancer.
Currently, we have only examined the pathways feeding into the biosynthesis of nucleotides.
However, it is extremely likely that Yap also directs cellular metabolism for the anabolic
synthesis of other biomolecular building blocks, such as lipids and amino acids. Our findings
of decreased glucose uptake and reduced glycolysis in the absence of Yap is supportive of
a role for Yap in fatty acid biosynthesis as most of the carbon for fatty acid synthesis is
derived from glucose. As we conducted polar metabolomics analyses, however, changes in
lipid metabolism would be largely undetectable in our current studies. Further suggesting
a role for Yap in lipid usage and absorption, in our yap knockout embryos, we find the
yolk, which is composed of lipids and other nutrients, to be improperly reabsorbed. In
addition, we observed that yap knockout embryos begin to show lethality at 6 dpf, which
corresponds to the transition from yolk-dependent nutrition to feeding (Anderson et al.,
2011). This suggests that yap knockout embryos had defects in nutrient uptake. Further
studies are likely to elucidate that Yap is able to coordinate multiple anabolic processes
for both detection of the metabolic environment and utilization of these resources for rapid
proliferation.
Our findings implicating Yap in regulating glucose uptake and metabolism, in conjunction
with the recently published papers regarding glucose availability to regulate Yap activity are
intriguing to ponder with regards to the ability of Yap to maintain stem cell populations.
Evidence shows that metabolites not only provide energy and support for proliferation, but
they also play a role in modulating pluripotency and differentiation (Shyh-Chang et al.,
2013). Studies in hematopoietic stem cells have shown that glucose and its transport are key
regulators of hematopoietic stem cell fate and proliferation (Miharada et al., 2011; Simsek
et al., 2010; Takubo et al., 2010; Harris et al., 2013; Yu et al., 2013; Oburoglu et al., 2014).
This is especially interesting in the context of the liver as a gradient glucose concentration is
found in mammalian livers dependent on nutritional status (Katz et al., 1977). Intriguingly,
though, most of liver glycolysis occurs in the centrilobular region of the hepatocyte lobule
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and in this region, it has been hypothesized the liver contains its hepatic adult progenitor
cell. It would be interesting to test whether glucose concentration plays a role in the ability
of adult stem cells to maintain their stemness in the context of Yap signaling.
With the alterations in metabolism that we see during development and in the pre-
neoplastic state, this opens more lines of inquiry as to whether these processes are also
modulated in the context of regeneration as many pathways conserved in development and
cancer are also found to be activated in the context of regeneration. The liver is the only
solid organ capable of regeneration in the human and holds tremendous ability for an ap-
propriate compensatory response to injury. With the liver’s unique ability to regenerate as
an adult and the causal association of continual injury and repair in the context of cirrhosis,
which is a major risk factor for hepatocellular carcinoma, it is tempting to speculate that
the Hippo pathway plays a central role to mediating liver regeneration both at the signal-
ing level of cellular division and the metabolic level to provide the necessary energy and
building blocks to the expanding hepatocyte pool. Already, the Hippo pathway has been
implicated in regeneration in the intestine of mammals as Yap is highly expressed during
regeneration in the stem cell crypts and where loss of Yap severely impairs sulfate-induced
intestinal regeneration (Cai et al., 2010; Zhao et al., 2011). The zebrafish has the unique
ability to regenerate many of its tissues, so using our models, determining the role of Yap in
fin, heart, and liver regeneration is feasible. This could provide especially elucidating in the
context of liver regeneration as liver injury can be induced in hepatocytes specifically using
nitroreductase (NTR) ablation (Curado et al., 2007a,b; Pisharath and Parsons, 2009). Liver
injury in these lf:CFP-NTR fish has revealed that biliary epithelial cells transdifferentiate
to mature hepatocytes during liver regeneration following hepatocyte ablation (Choi et al.,
2014; He et al., 2014). Interestingly, Yap has been found to play a critical role in hepato-
cyte dedifferentiation, and very high overexpression of Yap can change hepatocytes into a
biliary-ductal phenotype (Yimlamai et al., 2014). Based on these studies, it is reasonable
to hypothesize that Yap signaling might be critical for hepatocyte regeneration and organ
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regrowth by promoting plasticity of cell fate as well as pro-proliferative growth signals. Fur-
ther, based on our studies, it is likely that Yap directs the cellular metabolic program to
enhance anabolic pathways to provide for the rapid proliferation necessary for repair.
In the context of cancer, the ability of Yap to act as a central integrator of nutritional
biolmolecular availability and metabolic reprogramming for anabolic growth may provide
advantageous clonal selection in the context of tumor development. As tumor growth requires
survival in non-optimal, challenging growth environments, evolutionary pressures for survival
and optimizing nutrient utilization are necessary. For this reason, cells that are able to
reprogram cellular metabolism to generate the anabolic building blocks necessary for growth
are likely favored. As such, there may be selective pressure in those cells that have increased
Yap activity through gene amplification as they could acquire the ability to uptake more
glucose, through increased expression of glucose transporters, which will then allow Yap to
remain active and continue directing anabolic metabolism for proliferation.
More globally, with our findings of Yap as a regulator of cellular metabolism to aid in
the ability to proliferate, these bring about more questions of human physiology and the
importance of nutrition in the context of cancer. In studies where mice were injected with
aggressive human breast cancer cells, mortality rates were significantly reduced in the group
that were calorie restricted to hypoglycemic levels compared to normal fed mice, which had
better survival rates than the hyperglycemic group (Santisteban et al., 1985). Interestingly,
metformin, which decreases glucose production in the liver, has been shown to be extremely
beneficial in reducing the relative risk of liver cancer in epidemiological studies; however, in
other cancers this effect was not as great (Zhang et al., 2013). Metformin, recently, has been
shown to decrease Yap activity by increasing energy stress on cells (DeRan et al., 2014; Mo
et al., 2015). In combination with our findings of yap playing a role in glucose uptake and
diversion of its carbon backbone into nucleotides, this suggest that glucose availability could
be a potential therapeutic target and regulation of diet could be beneficial. Further, obesity
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is a known risk factor for cancer, so modulation of glucose levels could help in the prevention
of cancers in obese or hyperglycemic individuals.
Our increased understanding of the metabolic and molecular targets of Yap opens the
possibilities of new therapeutic strategies that can be aimed to interfere with Yap mediated
metabolic reprogramming. Our studies here include the usage of drugs targeting Glul and
Glut1 function, and we have conclusively demonstrated that Yap-mediated hyperproliferation
and growth can be reduced with these drugs. Unfortunately, the Glul inhibitor MSO cannot
be used in the clinical setting as it inhibits glutamine synthetase in the brain, resulting
in seizures. This does raise the need to find more biocompatible compounds that could be
targeted to modulate glutamine synthesis and glucose uptake. The zebrafish might provide to
be the optimal model as its ability to be used in wide chemical screens has already facilitated
the discovery of clinically beneficial treatments (Goessling et al., 2011; Cutler et al., 2013).
In conclusion, we show that Yap in the context of liver development and cancer is able
to reprogram normal cellular mechanisms of metabolism to promote the synthesis of macro-
molecular building blocks. Further, we establish the zebrafish as a powerful model for inves-
tigating the mechanisms of signaling pathways to control cellular metabolism in vivo. As we
have found modulation of Yap-driven cellular reprogramming to reduce Yap-driven growth,
these studies offer the promising molecular targets that may beneficial for patients with high
Yap activity cancers.
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